var title_f15_6_15456="Riedels thyroiditis Gross";
var content_f15_6_15456=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F60341&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F60341&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Riedel's thyroiditis: Surgical specimen",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 343px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gross thyroid specimen from a patient with Riedel's thyroiditis is characterized by a pale color due to replacement of the thyroid parenchyma with dense, avascular fibrous tissue. The surface of the specimen is covered with ink to indicate the surgical margin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Stephanie L Lee, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_6_15456=[""].join("\n");
var outline_f15_6_15456=null;
var title_f15_6_15457="Chest escharotomy";
var content_f15_6_15457=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F79668&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F79668&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 551px\">",
"   <div class=\"ttl\">",
"    Chest escharotomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 531px; height: 398px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This drawing shows the approximate location for chest escharotomy incisions. Although rarely required in the emergency department, such incisions may be needed should ventilation become difficult due to constriction of chest wall motion from eschar.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_6_15457=[""].join("\n");
var outline_f15_6_15457=null;
var title_f15_6_15458="Mechanism for medial epicondyle fracture";
var content_f15_6_15458=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F71928&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F71928&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mechanism for medial epicondyle fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 418px; height: 454px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hyperextension forces. When a person falls on the outstretched upper extremity, the wrist and fingers are forced into hyperextension (solid arrow), which places tension on the forearm flexor muscles. The sudden tension along with the normal valgus carrying angle tends to place a strong avulsion force on the medial epicondyle (open arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Beaty JH, Kasser JR. The elbow: Physeal fractures, apophyseal injuries of the distal humerus, avascular necrosis of the trochlea, and T-condylar fractures. In: Rockwood and Wilkins' Fractures in Children, 6th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_6_15458=[""].join("\n");
var outline_f15_6_15458=null;
var title_f15_6_15459="Squamous cell carcinoma of unknown primary site";
var content_f15_6_15459=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Squamous cell carcinoma of unknown primary site",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/6/15459/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/6/15459/contributors\">",
"     John D Hainsworth, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/6/15459/contributors\">",
"     F Anthony Greco, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/6/15459/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/6/15459/contributors\">",
"     George P Canellos, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/6/15459/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/6/15459/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/6/15459/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cancer of unknown primary site (CUP) is a relatively common clinical entity, accounting for 4 to 5 percent of all invasive cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15459/abstract/1\">",
"     1",
"    </a>",
"    ]. Within this category, tumors from many primary sites with varying biology are represented. Squamous cell carcinomas (SCCs) comprise approximately 5 percent of CUPs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/26/14758?source=see_link\">",
"     \"Overview of the classification and management of cancers of unknown primary site\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Effective treatment is available for some patients with SCC of unknown primary site who fit certain clinical syndromes, particularly those with involvement of the cervical or inguinal lymph nodes. For this reason, appropriate evaluation of these patients is essential prior to embarking on treatment.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cervical lymph nodes are the most common metastatic site for SCCs. Patients with tumor involving upper or mid level cervical nodes are likely to have a primary cancer of the head and neck. In contrast, a lung primary should be suspected in those with lower cervical lymph nodes.",
"     </li>",
"     <li>",
"      SCCs of unknown primary site involving inguinal lymph nodes usually arise from a primary anogenital malignancy. Some of these patients may be curable with locoregional therapy directed against their primary tumor.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The diagnosis and management of patients with squamous cell carcinoma (SCC) of unknown primary site other than those presumed to be of head and neck origin is reviewed here. The evaluation and treatment of head and neck squamous carcinoma of unknown primary is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/28/19911?source=see_link\">",
"     \"Head and neck squamous cell carcinoma of unknown primary\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     UPPER OR MID CERVICAL LYMPH NODES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with involvement of the upper or mid cervical nodes are usually middle-aged or elderly, and many have a history of substantial tobacco",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    alcohol use. A primary tumor in the head and neck region should be suspected and should be the focus of the initial diagnostic evaluation. The diagnostic evaluation and subsequent treatment of these patients is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/28/19911?source=see_link&amp;anchor=H26830842#H26830842\">",
"     \"Head and neck squamous cell carcinoma of unknown primary\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/28/19911?source=see_link&amp;anchor=H26830878#H26830878\">",
"     \"Head and neck squamous cell carcinoma of unknown primary\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     LOWER CERVICAL OR SUPRACLAVICULAR NODES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A primary lung cancer should be suspected when lower cervical or supraclavicular nodes are involved, although a head and neck primary is possible. Fiberoptic bronchoscopy is indicated if the chest radiograph and head and neck examination are unrevealing.",
"   </p>",
"   <p>",
"    If the fiberoptic bronchoscopy reveals a primary bronchogenic cancer, patient management is the same as that for advanced non-small cell lung cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/61/13273?source=see_link\">",
"     \"Overview of the initial evaluation, treatment and prognosis of lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the absence of a detectable primary site, the results are poor. Nevertheless, patients with no detectable disease below the clavicle should be treated with the same approach as patients with upper cervical nodes, since occasional patients will have long-term disease-free survival.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     INGUINAL LYMPH NODE DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vast majority of patients with SCC involving inguinal lymph nodes have a detectable primary site in the genital or anorectal area (including the surrounding skin).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In women, careful examination of the vulva, vagina and cervix is important, with biopsy of any suspicious areas.",
"     </li>",
"     <li>",
"      Men should undergo a careful inspection of the penis.",
"     </li>",
"     <li>",
"      In both sexes, digital rectal examination and anoscopy should be performed to exclude anorectal lesions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Identification of a primary site in these patients is important, since therapy is potentially curative for patients with carcinomas arising in the anogenital region. For the occasional patient in whom no primary site is identified, lymphadenectomy with or without postoperative radiation therapy to the inguinal nodal basin sometimes results in long-term survival [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15459/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although experience is limited in this uncommon group of patients, recent success with combined chemotherapy and radiation in other cancers originating in this region (ie, cervix, anus, bladder) suggest a potential role for this approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     OTHER METASTATIC SITES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Metastatic SCC in areas other than the cervical or inguinal lymph nodes usually represents metastasis from a primary lung cancer. CT of the chest and fiberoptic bronchoscopy should be considered if other clinical features suggest the possibility of lung cancer. Chemotherapy with regimens employed in the treatment of non-small cell lung cancer may be considered in patients with good performance status. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34666?source=see_link\">",
"     \"Initial systemic chemotherapy for advanced non-small cell lung cancer without an epidermal growth factor receptor mutation or the ALK fusion oncogene\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with the diagnosis of poorly differentiated SCC should be evaluated carefully, particularly if other clinical features are unusual for lung cancer (eg, young patient, nonsmoker, unusual metastatic sites). This histologic diagnosis is sometimes based upon scant histologic criteria and may include patients with poorly differentiated carcinoma, in whom other diagnoses should be considered. For this reason, additional pathologic evaluation with immunohistochemical stains, molecular tumor profiling, or electron microscopy should be considered in such patients. If the diagnosis is still unclear, a trial of therapy for poorly differentiated carcinoma should be considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H606939224\">",
"    <span class=\"h1\">",
"     NUT MIDLINE CARCINOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;NUT midline carcinomas are aggressive, poorly differentiated tumors that include variable degrees of squamous differentiation in approximately one-half of cases. These tumors are defined by the presence of a chromosomal rearrangement of the NUT gene, and have a distinct clinical presentation and clinical course category [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15459/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with an occult squamous cell carcinoma (SCC), the initial diagnostic evaluation should attempt to identify the primary site, which can serve as the basis for optimizing treatment. The initial diagnostic evaluation is based upon the site of disease involvement:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients presenting with squamous cell carcinoma (SCC) involving the mid or upper cervical lymph nodes and without an obvious primary, diagnostic evaluation should focus primarily on identifying an occult head and neck primary. If no primary can be identified, such patients should be treated for locally advanced cancer of the head and neck rather than with empiric chemotherapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/28/19911?source=see_link\">",
"       \"Head and neck squamous cell carcinoma of unknown primary\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with SCC involving lower cervical or supraclavicular lymph nodes, the initial evaluation should include a search for an occult lung primary as well as an occult head and neck lesion. For patients with no identifiable primary tumor, we suggest treatment for an occult head and neck tumor rather than with empiric chemotherapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Lower cervical or supraclavicular nodes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with SCC involving inguinal lymph nodes, an intensive search should be made for an anogenital primary tumor, which can be identified in most cases. For the occasional patient in whom no primary site can be identified, we suggest lymphadenectomy with or without postoperative radiation therapy to the inguinal nodal basin rather than with empiric chemotherapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Inguinal lymph node disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      SCC arising in other sites is rare. If no primary tumor can be identified, we suggest empiric systemic chemotherapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We use a regimen such as those for non-small cell lung cancer. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Other metastatic sites'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15459/abstract/1\">",
"      Greco FA, Hainsworth JD. Introduction: unknown primary cancer. Semin Oncol 2009; 36:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15459/abstract/2\">",
"      Guarischi A, Keane TJ, Elhakim T. Metastatic inguinal nodes from an unknown primary neoplasm. A review of 56 cases. Cancer 1987; 59:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15459/abstract/3\">",
"      French CA. Pathogenesis of NUT midline carcinoma. Annu Rev Pathol 2012; 7:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15459/abstract/4\">",
"      Bauer DE, Mitchell CM, Strait KM, et al. Clinicopathologic features and long-term outcomes of NUT midline carcinoma. Clin Cancer Res 2012; 18:5773.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4880 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-180.241.123.62-8D972B75FE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_6_15459=[""].join("\n");
var outline_f15_6_15459=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      UPPER OR MID CERVICAL LYMPH NODES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      LOWER CERVICAL OR SUPRACLAVICULAR NODES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      INGUINAL LYMPH NODE DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      OTHER METASTATIC SITES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H606939224\">",
"      NUT MIDLINE CARCINOMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/28/19911?source=related_link\">",
"      Head and neck squamous cell carcinoma of unknown primary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34666?source=related_link\">",
"      Initial systemic chemotherapy for advanced non-small cell lung cancer without an epidermal growth factor receptor mutation or the ALK fusion oncogene",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/26/14758?source=related_link\">",
"      Overview of the classification and management of cancers of unknown primary site",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/61/13273?source=related_link\">",
"      Overview of the initial evaluation, treatment and prognosis of lung cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_6_15460="Clotrimazole (oral): Pediatric drug information";
var content_f15_6_15460=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Clotrimazole (oral): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?34/60/35780?source=see_link\">",
"    see \"Clotrimazole (oral): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?5/44/5828?source=see_link\">",
"    see \"Clotrimazole (oral): Patient drug information \"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10576064\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antifungal Agent, Oral Nonabsorbed",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10576086\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/60/35780?source=see_link\">",
"      see \"Clotrimazole (oral): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children &gt;3 years and Adults: Oral: 10 mg troche dissolved slowly 5 times/day",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8011732\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Troche, oral: 10 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8011647\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10576087\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dissolve lozenge (troche) in mouth over 15-30 minutes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10576065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of susceptible fungal infections, including oropharyngeal candidiasis; limited data suggests that the use of clotrimazole troches may be effective for prophylaxis against oropharyngeal candidiasis in neutropenic patients",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8011644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Clotrimazole may be confused with co-trimoxazole",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Mycelex may be confused with Myoflex&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Cloderm: Brand name for clotrimazole [Germany], but also brand name for alclomethasone [Indonesia]; clobetasol [China, India, Malaysia, Singapore, Thailand]; clocortolone [U.S., Canada]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Canesten [multiple international markets] may be confused with Canesten Bifonazol Comp brand name for bifonazole/urea [Austria]; Canesten Extra brand name for bifonazole [China, Germany]; Canesten Extra Nagelset brand name for bifonazole/urea [Denmark]; Canesten Fluconazole brand name for fluconazole [New Zealand]; Canesten Oasis brand name for sodium citrate [Great Britain]; Canesten Once Daily brand name for bifonazole [Australia]; Canesten Oral brand name for fluconazole [United Kingdom]; Cenestin brand name for estrogens (conjugated A/synthetic) [U.S., Canada]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Mycelex: Brand name for clotrimazole [U.S.] may be confused with Mucolex brand name for bromhexine [Malaysia]; carbocisteine [Thailand]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F8011657\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Abnormal liver function tests",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10576066\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to clotrimazole or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10576068\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Safety and effectiveness of clotrimazole lozenges (troches) in children &lt;3 years of age have not been established",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10576067\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Clotrimazole troches should not be used for treatment of systemic fungal infection",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F8011660\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak), CYP2A6 (weak), CYP2B6 (weak), CYP2C19 (weak), CYP2C8 (weak), CYP2C9 (weak), CYP2D6 (weak), CYP2E1 (weak), CYP3A4 (moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8011661\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Avanafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Avanafil.  Management: The maximum avanafil adult dose is 50 mg per 24-hour period when used together with a moderate CYP3A4 inhibitor.  Patients receiving such a combination should also be monitored more closely for evidence of adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Systemic, Oral Inhalation): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Budesonide (Systemic, Oral Inhalation).  Management: Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor.  This interaction is likely less severe with orally inhaled budesonide.  Monitor patients closely for signs/symptoms of corticosteroid excess.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.  Management: Reduce colchicine dose as directed when using with a moderate CYP3A4 inhibitor, and increase monitoring for colchicine-related toxicity.  Use extra caution in patients with impaired renal and/or hepatic function.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eplerenone.  Management: When used concomitantly with moderate inhibitors of CYP3A4, eplerenone dosing recommendations may vary depending on international labeling. Consult appropriate labeling for specific recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Everolimus.  Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of FentaNYL.  Management: Monitor patients extra closely for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Halofantrine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Halofantrine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivabradine.  Management: In patients with a resting heart rate over 60 beats per minute receiving a moderate CYP3A4 inhibitor, ivabradine initiation at an adult dose of 2.5 mg twice daily may be considered.  Monitor heart rate closely under these circumstances.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivacaftor.  Management: Decrease ivacaftor dose to 150 mg daily in patients also receiving moderate CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lomitapide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lurasidone.  Management: U.S. labeling: start at 20 mg/day and limit to max of 80 mg/day with moderate CYP3A4 inhibitor.  Canadian labeling: limit to max of 40 mg/day with moderate CYP3A4 inhibitor; avoid concomitant use of grapefruit products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of Pimecrolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ranolazine.  Management: Limit the ranolazine adult dose to a maximum of 500 mg twice daily in patients concurrently receiving moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil, erythromycin, etc.).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saccharomyces boulardii: Antifungal Agents may diminish the therapeutic effect of Saccharomyces boulardii.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salmeterol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Salmeterol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Clotrimazole (Oral) may increase the serum concentration of Tacrolimus (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tolvaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vilazodone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vilazodone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Zuclopenthixol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8011650\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9775509\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In animal reproduction studies, adverse events were observed with oral administration of clotrimazole.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10576088\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Periodic liver function tests",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10576084\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Binds to phospholipids in the fungal cell membrane altering cell wall permeability, resulting in loss of essential intracellular elements",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10576085\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Distribution: Following oral administration, clotrimazole is present in saliva for up to 3 hours following 30 minutes of dissolution time in the mouth",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15955 Version 27.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-83.177.194.223-A277839E2F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_6_15460=[""].join("\n");
var outline_f15_6_15460=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10576064\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10576086\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8011732\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8011647\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10576087\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10576065\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8011644\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8011657\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10576066\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10576068\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10576067\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8011660\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8011661\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8011650\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9775509\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10576088\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10576084\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10576085\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15955\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15955|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/60/35780?source=related_link\">",
"      Clotrimazole (oral): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?5/44/5828?source=related_link\">",
"      Clotrimazole (oral): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?28/61/29652?source=related_link\">",
"      Clotrimazole (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?40/37/41556?source=related_link\">",
"      Clotrimazole (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/28/13763?source=related_link\">",
"      Clotrimazole (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_6_15461="RB ILD CT I";
var content_f15_6_15461=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F68487%7EPULM%2F82553&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F68487%7EPULM%2F82553&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Respiratory bronchiolitis-associated interstitial lung disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 374px; height: 220px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CT scan (5 mm thick section) in a 35-year-old woman with heavy smoking history and progressive dyspnea with exertion shows extensive ground-glass opacities. The plain chest film was normal. The diagnosis was confirmed by open lung biopsy. Symptoms improved following smoking cessation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Talmadge E King Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Respiratory bronchiolitis-associated interstitial lung disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 370px; height: 287px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High resolution CT scan (1.5 mm thick section) in a 35-year-old woman with heavy smoking history and progressive dyspnea with exertion. Extensive ground-glass opacities are seen more clearly than on conventional CT scan (5 mm thick section).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Talmadge E King Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_6_15461=[""].join("\n");
var outline_f15_6_15461=null;
var title_f15_6_15462="Lateral medullary infarct";
var content_f15_6_15462=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F62175&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F62175&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Medulla oblongata",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 336px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The usual location of lateral medullary infarcts is hatch-marked in the upper right of the figure. The anatomical structures are labeled on the diagram.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_6_15462=[""].join("\n");
var outline_f15_6_15462=null;
var title_f15_6_15463="Intermediate case 5";
var content_f15_6_15463=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F57553&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F57553&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intermediate case 5",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 422px; height: 127px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal rhythm strip",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 165px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Morton F Arnsdorf, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_6_15463=[""].join("\n");
var outline_f15_6_15463=null;
var title_f15_6_15464="Primary cutaneous follicle center lymphoma";
var content_f15_6_15464=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Primary cutaneous follicle center lymphoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/6/15464/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/6/15464/contributors\">",
"     Eric Jacobsen, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/6/15464/contributors\">",
"     Arnold S Freedman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/6/15464/contributors\">",
"     Rein Willemze, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/6/15464/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/6/15464/contributors\">",
"     Timothy M Kuzel, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/6/15464/contributors\">",
"     John A Zic, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/6/15464/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/6/15464/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/6/15464/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary cutaneous B cell lymphoma (PCBCL) refers to those cases of B cell lymphoma that present in the skin when there is no evidence of extracutaneous disease at the time of diagnosis and after the completion of an initial staging evaluation. The 2008 World Health Organization (WHO) classification system defines three main subtypes of PCBCL [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15464/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Primary cutaneous follicle center lymphoma (PCFCL)",
"     </li>",
"     <li>",
"      Primary cutaneous large B cell lymphoma, leg type",
"     </li>",
"     <li>",
"      Primary cutaneous marginal zone lymphoma (PCMZL), which is included in the broader category of extranodal marginal zone B cell lymphoma",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These appear to be unique entities with differing clinical presentations, pathologic features, and prognosis. The approach to treatment also differs between subtypes. This topic review will discuss primary cutaneous follicle center lymphoma. This entity was previously known as primary cutaneous follicle center cell lymphoma (PCFCCL) under the European Organization for Research and Treatment of Cancer (EORTC) classification and contains cases that may have previously be classified as cutaneous follicle center lymphoma or diffuse large B cell lymphoma under the 2001 WHO classification.",
"   </p>",
"   <p>",
"    The other PCBCL subtypes and other forms of cutaneous lymphoma (ie, T cell lymphoma, mycosis fungoides) are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/9/26776?source=see_link\">",
"     \"Primary cutaneous marginal zone lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/49/26391?source=see_link\">",
"     \"Primary cutaneous large B cell lymphoma, leg type\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/32/4618?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 25 percent of all non-Hodgkin lymphoma (NHL) cases will present at an extranodal site without systemic involvement. The skin is the second most common primary extranodal site, second in frequency only to the gastrointestinal tract [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15464/abstract/2\">",
"     2",
"    </a>",
"    ]. The overall incidence of primary cutaneous lymphomas in Western countries is estimated to be 0.5 to 1 case per 100,000 people annually. Of these, approximately 20 percent represent primary cutaneous B cell lymphoma (PCBCL) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15464/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Primary cutaneous follicle center lymphoma (PCFCL) is the most common PCBCL, accounting for approximately 60 percent of such cases [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15464/abstract/1,5-7\">",
"     1,5-7",
"    </a>",
"    ]. Although the disease does occur in patients as young as 20 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15464/abstract/6,8\">",
"     6,8",
"    </a>",
"    ], it is primarily a disease of middle aged to older patients, with a median age at onset of 51 and a male:female ratio of approximately 1.5:1 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15464/abstract/1,9,10\">",
"     1,9,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no clearly defined risk factors for developing this disease and there is no identifiable hereditary tendency.",
"   </p>",
"   <p>",
"    Pathogenetic links between PCBCL and Borrelia burgdorferi infection have been established in Europe, but North American and Asian case series have thus far failed to demonstrate a similar relationship. &nbsp;Borrelia burgdorferi infection is seen more commonly in primary cutaneous marginal zone lymphoma, and only rarely in PCFCL. Although several case reports have suggested a link between PCBCL and viral infection (eg, Epstein-Barr virus, HIV, and hepatitis C virus), no definitive evidence exists. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/9/26776?source=see_link&amp;anchor=H3#H3\">",
"     \"Primary cutaneous marginal zone lymphoma\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary cutaneous follicle center lymphoma (PCFCL) typically presents with solitary or grouped firm erythematous, painless, nonpruritic papules, plaques, or tumors with a predilection for the head, neck, and trunk (",
"    <a class=\"graphic graphic_picture graphicRef73842 graphicRef50985 \" href=\"UTD.htm?4/27/4537\">",
"     picture 1A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15464/abstract/7,11,12\">",
"     7,11,12",
"    </a>",
"    ]. Approximately 5 percent of patients may have lesions on the legs while 15 percent may present with multifocal skin lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15464/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The lesions are generally smooth and do not typically ulcerate; superficial scaling may be present [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15464/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Surrounding annular erythema, which may be papular, has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15464/abstract/15\">",
"     15",
"    </a>",
"    ]. Disseminated lesions are rare, although cases with a dermatomal distribution have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15464/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. A multicenter retrospective study described the presence of small papular skin lesions located at a distance of the main affected area in 3 of 24 patients with a PCFCL [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15464/abstract/18\">",
"     18",
"    </a>",
"    ]. Interestingly, these distant lesions resolved spontaneously in all three patients.",
"   </p>",
"   <p>",
"    The lesions tend to progress slowly and may be present for more than 20 years before a diagnosis is established; a latent phase of several years is the norm [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15464/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Systemic \"B\" symptoms (ie, fever, weight loss, night sweats) were reported in only 2 of 84 cases in one series [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15464/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PATHOLOGIC FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of primary cutaneous follicle center lymphoma (PCFCL) is made based upon a pathologic evaluation of a skin biopsy in a patient who has no evidence of systemic lymphoma upon staging studies. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Staging'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Morphology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin biopsy can demonstrate a range of infiltrating malignant cells from perivascular and periadnexal to diffuse patterns that almost always spare the epidermis. &nbsp;The lesions are composed of predominantly medium-sized and large centrocytes (large cleaved follicle center cells) and variable proportions of centroblasts (large follicle center cells with prominent nucleoli) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15464/abstract/5,22\">",
"     5,22",
"    </a>",
"    ]. Growth can be in a follicular, follicular and diffuse, or diffuse pattern. In more advanced PCFCL, the follicles may be less pronounced, or absent.",
"   </p>",
"   <p>",
"    Unlike nodal follicular lymphoma, PCFCL is not routinely graded since no reliable correlation between grading and prognosis has yet been established.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Immunophenotype",
"    </span>",
"    &nbsp;&mdash;&nbsp;PCFCL is a B cell malignancy thought to arise from mature germinal center cells. Virtually all cases express pan B cell antigens (CD19, CD20, CD79a), but are usually immunoglobulin and always CD5 negative [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15464/abstract/5,23\">",
"     5,23",
"    </a>",
"    ]. Most cases express B cell leukemia 6 (BCL6) and do not express B cell",
"    <span class=\"nowrap\">",
"     leukemia/lymphoma",
"    </span>",
"    2 (BCL-2) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15464/abstract/18\">",
"     18",
"    </a>",
"    ]. CD10 expression is variable [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15464/abstract/24\">",
"     24",
"    </a>",
"    ].",
"    <span class=\"nowrap\">",
"     MUM1/IRF4",
"    </span>",
"    is negative [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15464/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The genetic classification of PCFCL has been fraught with difficulty. True follicular lymphomas are generally believed to derive from germinal center B cells, and the majority of nodal follicular lymphomas have a t(14;18) translocation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bcl-2 gene rearrangement [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15464/abstract/26\">",
"     26",
"    </a>",
"    ]. In contrast, the reported incidence of bcl-2 expression and the t(14;18) translocation in PCFCL has ranged from zero [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15464/abstract/18,27,28\">",
"     18,27,28",
"    </a>",
"    ] to as high as 30 to 40 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15464/abstract/8,29\">",
"     8,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PCFCL shows the gene expression profile of germinal center&ndash;like large B cell lymphomas, and often shows amplifications of the C-REL gene [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15464/abstract/25,30\">",
"     25,30",
"    </a>",
"    ]. Deletion of chromosome 14q32.33 has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15464/abstract/30\">",
"     30",
"    </a>",
"    ]. In contrast to PCLBCL, LT, deletions of a small region on chromosome 9p21.3 containing the CDKN2a and CDKN2B gene loci is not or rarely found in PCFCL [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15464/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29127?source=see_link&amp;anchor=H17219010#H17219010\">",
"     \"Prognosis of diffuse large B cell lymphoma\", section on 'Overview'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of PCFCL requires a representative biopsy of involved skin and the exclusion of non-cutaneous disease. Excisional biopsies are preferred to punch biopsies, but if a punch biopsy is taken, the diameter should be at least 4 millimeters. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Staging'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The biopsy specimen is evaluated for morphology, growth pattern, and immunohistochemical studies. A typical biopsy of PFCL demonstrates an epidermis-sparing B cell infiltrate comprised of centrocytes and centroblasts with a follicular or diffuse pattern. B cell lineage is confirmed by the presence of CD20 or CD79a and the absence of CD3.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Systemic lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Non-Hodgkin lymphoma (NHL) may involve the skin either as a primary entity or as the result of cutaneous spread from systemic disease. An estimated 6 to 10 percent of patients with systemic B cell NHL will develop cutaneous disease at some point in their illness [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15464/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Biopsy specimens from follicular lymphoma (FL) can resemble those of PCFCL in their morphology and immunophenotype. Characteristically, the tumor cells of FL express monotypic immunoglobulin light chain, CD20, CD10, and BCL-6 and are negative for CD5 and CD23. The vast majority (&gt;85 percent) of FL tumors express BCL-2, and show the t(14;18).",
"   </p>",
"   <p>",
"    In contrast, PCFCL only rarely express immunoglobulin and most cases are Bcl-2 negative. CD-10 expression is variable. Strong expression of Bcl-2, Bcl-6, and CD10 should raise the suspicion of systemic follicular lymphoma with skin involvement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/46/25322?source=see_link\">",
"     \"Clinical manifestations, pathologic features, diagnosis, and prognosis of follicular lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Reactive infiltrate",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the most important diagnostic considerations in all primary cutaneous B cell lymphoma (PCBCL) subtypes is differentiating a neoplastic B cell infiltrate from a reactive infiltrate. In general, PCBCLs will demonstrate clonal light chain restriction, while reactive processes will overwhelmingly be polyclonal [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15464/abstract/32\">",
"     32",
"    </a>",
"    ]. In addition, Ki-67 staining can determine the proliferative fraction and aid in the differentiation between neoplastic and reactive follicles; the Ki-67+ fraction is lower in PCFCL than in reactive follicles. However, in PCFCL with a diffuse growth pattern, the proliferative fraction is generally &gt;75 percent.",
"   </p>",
"   <p>",
"    Unlike the follicles seen in cutaneous follicular hyperplasias, the follicles in PCFCL are ill-defined, have a decreased mantle zone, lack tingible body macrophages, and show a monotonous proliferation of BCL6+ follicle center cells in a network of CD21+ or CD35+ follicular dendritic cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Primary cutaneous diffuse large B cell lymphoma, leg type",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is extremely important to differentiate PCFCL from primary cutaneous diffuse large B cell lymphoma, leg type since the latter is far more aggressive and requires a different treatment approach. Despite its name, primary cutaneous diffuse large B cell lymphoma, leg type can occur at sites other than the leg. These lesions have a diffuse pattern or a monotonous proliferation of centroblasts and immunoblasts on biopsy, and, in contrast to PCFCL, strongly express Bcl-2, Mum-1, Fox-P1 and IgM. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/49/26391?source=see_link\">",
"     \"Primary cutaneous large B cell lymphoma, leg type\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Primary cutaneous marginal zone lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;PCFCL can be differentiated from primary cutaneous marginal zone lymphoma (PCMZL) based upon differences in clinical presentation and pathologic findings on the skin biopsy. PCFCL is characterized by a diffuse infiltrate of large cleaved cells (large centrocytes) with a Bcl-6+, Bcl-2-,",
"    <span class=\"nowrap\">",
"     CD10-/+",
"    </span>",
"    phenotype. In contrast, the neoplastic cells of PCMZL have a Bcl-6-, Bcl-2+, CD10- phenotype. Moreover, monotypic Ig light chain expression by the lymphoplasmacytoid and plasma cells (typically located at the periphery of the nodular infiltrates and subepidermally) is a hallmark of PCMZL and rarely observed in PCFCL. Morphologically, differentiation between PCFCL with a (partly) follicular growth pattern and PCMZL with reactive follicular structures may sometimes be difficult. However, in such cases, the differential expression of Bcl-6, Bcl-2 and CD10 may result in the correct diagnosis. It should be noted that colonization of follicular structures by neoplastic marginal zone cells, as often observed in extranodal marginal zone lymphomas arising at other sites, is rarely seen in PCMZL. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/9/26776?source=see_link\">",
"     \"Primary cutaneous marginal zone lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Cutaneous T cell lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cutaneous T cell lymphomas can be distinguished from cutaneous B cell lymphomas through their expression of T cell markers such as CD2, CD3, and CD5. In addition, cutaneous T cell lymphomas can be identified by T cell receptor (TCR) gene rearrangement studies. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/32/4618?source=see_link&amp;anchor=H19#H19\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Intravascular lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravascular large B cell lymphoma is a distinctly uncommon non-Hodgkin lymphoma variant that typically presents as multiple, erythematous tender nodules, tumors, or telangiectasias in older patients. Isolated involvement of the skin does occur, but the disease more frequently affects multiple organ systems, including the central nervous system (CNS), kidneys, and adrenals producing a wide variety of symptoms, ranging from generalized confusion or dementia to focal motor and sensory deficits. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/12/13511?source=see_link\">",
"     \"Intravascular large cell lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     STAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;At the time of diagnosis, patients with suspected primary cutaneous lymphoma should undergo a complete history, physical examination, and staging evaluation. This evaluation both confirms the diagnosis of primary cutaneous lymphoma by excluding involvement of other sites and provides information to guide treatment. We perform the following studies as part of this staging evaluation :",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Laboratory studies include a complete blood count, comprehensive serum chemistries, and serum lactate dehydrogenase (LDH). Flow cytometry of the peripheral blood mononuclear cells is indicated for patients with a lymphocytosis. In addition, all patients with newly diagnosed lymphoma should undergo HIV testing.",
"     </li>",
"     <li>",
"      Radiographic imaging with a contrast-enhanced computed tomography (CT) scan of the chest, abdomen and pelvis or combined positron emission tomography",
"      <span class=\"nowrap\">",
"       (PET)/CT",
"      </span>",
"      scan should be performed. The neck should be included if there is palpable adenopathy. Magnetic resonance imaging (MRI) is often substituted for patients who are unable to safely undergo CT scan. Suspicious lesions should be biopsied.",
"     </li>",
"     <li>",
"      Unilateral bone marrow aspiration and biopsy. We usually perform a bone marrow evaluation for patients with cytopenias and for all patients prior to the initiation of therapy. This is principally because a bone marrow biopsy demonstrating involvement would lead the clinician to offer systemic therapy rather than skin directed therapy such as radiation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If any of the above demonstrates disease outside of the skin in a newly diagnosed patient, strong consideration should be given to the diagnosis of systemic lymphoma. The presence of \"B\" symptoms, abnormal blood counts, elevated beta-2-microglobulin, or an elevated LDH should also raise suspicion of a systemic lymphoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15658?source=see_link\">",
"     \"Initial evaluation and staging of non-Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Using information gathered from the above tests, patients are staged using the",
"    <span class=\"nowrap\">",
"     EORTC/International",
"    </span>",
"    Society for Cutaneous Lymphomas (ISCL) TNM (tumor, node, metastases) staging system for primary cutaneous lymphomas other than mycosis fungoides and the S&eacute;zary syndrome (",
"    <a class=\"graphic graphic_table graphicRef65110 \" href=\"UTD.htm?10/56/11149\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15464/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;PCFCL is a rare disorder; accordingly, large trials and a consensus regarding therapy are lacking. The published data regarding treatment consist entirely of retrospective reviews and anecdotal reports. The generally indolent nature of PCFCL has shifted focus to localized, low morbidity modalities such as radiotherapy.",
"   </p>",
"   <p>",
"    In general, our treatment approach depends upon the number of lesions, their location, and the presence of symptoms attributable to the lesions (eg, pruritus). Systemic spread and disease related deaths are uncommon, occurring in roughly 10 and 5 percent of patients, respectively, over a 10-year period [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15464/abstract/18,34-36\">",
"     18,34-36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If left untreated, the lesions typically increase in size gradually over years and only disseminate to extracutaneous sites in approximately 10 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15464/abstract/1\">",
"     1",
"    </a>",
"    ]. Our treatment approach is largely based upon observations from the largest literature review that reported outcomes of 713 patients with PCFCL treated with different modalities as described below [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15464/abstract/37\">",
"     37",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Radiation therapy &mdash; Compilation of data on 460 patients treated with 20 to 54 Gy of radiation revealed a 99 percent complete response rate. The relapse rate varied from 30 to 76 percent in the largest studies [",
"      <a class=\"abstract\" href=\"UTD.htm?15/6/15464/abstract/37\">",
"       37",
"      </a>",
"      ]. This variance may reflect differences in radiation technique. Studies that included a smaller margin of healthy appearing skin in the radiation field reported in-field and marginal recurrences that were not found in studies that used larger margins. One study demonstrated responses to lower doses (4 Gy in two fractions) of radiation [",
"      <a class=\"abstract\" href=\"UTD.htm?15/6/15464/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Excision &mdash; Of 93 patients treated with complete surgical excision 98 percent obtained a complete response, but skin relapse was seen in approximately 40 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?15/6/15464/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Intralesional interferon alpha &mdash; Seven cases treated with intralesional interferon alpha (IFN) have been reported in the literature with all obtaining a complete response [",
"      <a class=\"abstract\" href=\"UTD.htm?15/6/15464/abstract/37\">",
"       37",
"      </a>",
"      ]. Although two patients relapsed and were successfully treated with a second course of intralesional IFN, follow-up of these patients has been short.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       Rituximab",
"      </a>",
"      &mdash; A small number of patients treated with intralesional (12 patients) or systemic (28 patients) rituximab have been reported with complete response rates of 83 and 75 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?15/6/15464/abstract/37\">",
"       37",
"      </a>",
"      ]. Relapses in the skin were seen in a little less than half of patients. Another trial of intralesional rituximab in 35 patients with PCFCL or PCMZL confirmed these early findings, reporting a complete response (CR) in 71 percent with a median time to CR of eight weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?15/6/15464/abstract/39\">",
"       39",
"      </a>",
"      ]. Median disease-free survival was approximately two years.",
"     </li>",
"     <li>",
"      Multiagent chemotherapy &mdash; Cumulative data on 104 patients treated with multiagent chemotherapy, mostly CHOP-like, demonstrated complete responses in 85 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?15/6/15464/abstract/37\">",
"       37",
"      </a>",
"      ]. Most patients presented with large tumor burdens and relapses were seen in 48 percent. There are even fewer reports of R-CHOP in this disease with mixed results.",
"     </li>",
"     <li>",
"      There have also been a few reports of multiagent chemotherapy followed by involved field radiation therapy as used in diffuse large B cell lymphoma. Cumulative data on seven patients reported complete responses in all with one developing relapse [",
"      <a class=\"abstract\" href=\"UTD.htm?15/6/15464/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon the observational data described above, the following describes our approach to the patient with PCFCL:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with a solitary lesion or lesions that can be contained in one radiation field, we suggest treatment with radiation therapy rather than chemotherapy or surgical excision. At least 30 Gy of radiation should be delivered to a field that includes a margin of at least 1 to 1.5 cm of uninvolved skin. Alternatively, small solitary lesions may be excised surgically or patients may be observed.",
"      <br/>",
"      <br/>",
"      Our preference for the use of radiation therapy is largely because almost all patients treated with radiation therapy are able to obtain a complete response with low toxicity and a low relapse rate when administered with appropriate margins of normal appearing tissue. Radiation toxicity varies by site and cases that require radiation to fields that have high rates of complications may benefit from alternative therapy or observation. Examples include young women in whom the breast would have to be irradiated and in those in whom radiation to the salivary glands might lead to loss of their teeth.",
"     </li>",
"     <li>",
"      For patients with a few scattered lesions not able to fit in one radiation field, we suggest treatment with either radiation therapy to all visible lesions or initial observation rather than excision or multiagent chemotherapy. If initial observation is chosen, radiation treatment can be administered to symptomatic skin lesions as they develop.",
"     </li>",
"     <li>",
"      For patients with extensive, diffuse disease, we suggest treatment with single agent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      rather than observation, radiation therapy, or multiagent chemotherapy. We reserve combination chemotherapy for the rare case with extremely extensive, symptomatic disease or those who fail to respond to initial rituximab.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     ASSESSING DISEASE RESPONSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;We evaluate and restage patients 8 to 12 weeks after the completion of therapy. Restaging should consist of repeating all laboratory, clinical, and radiographic examinations used to stage the disease at presentation though we typically do not repeat a bone marrow biopsy unless there is suspicion of new bone marrow involvement such as an abnormal complete blood count.",
"   </p>",
"   <p>",
"    Following the completion of therapy, restaging, and documentation of complete remission, patients are seen at periodic intervals to monitor for treatment complications and assess for possible relapse. The frequency and extent of these visits depends upon the comfort of both the patient and physician. When planning the post-treatment surveillance strategy, care should be taken to limit the number of radiologic scans, particularly in younger individuals, given concerns about radiation exposure and the risk for second malignancies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21785?source=see_link\">",
"     \"Radiation-related risks of imaging studies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients who are in complete remission, we typically re-evaluate with a physical examination every three months for the first two years following therapy. The frequency of clinic visits is then decreased thereafter. We do not use imaging studies or blood examinations in the routine follow-up of asymptomatic individuals. This is principally because recurrences are almost always detected by clinical examination. In a retrospective analysis that included 20 patients with PCFCL followed for a median of 66 months, there were 23 episodes of recurrence, all of which were identified by physical examination [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15464/abstract/40\">",
"     40",
"    </a>",
"    ]. Neither blood examinations nor imaging procedures established recurrence or progression in any patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     TREATMENT AT RELAPSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 30 percent of patients initially treated with radiation therapy will relapse. Most relapses are confined to the skin. If they appear outside of the prior radiation field, most will respond to radiation therapy. If they occur inside the radiation field, surgical excision or single agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    may be used. While multiagent chemotherapy remains an option for difficult to treat disease, it is rarely necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21004020\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with PCFCL usually have an indolent clinical course. If left untreated, the lesions typically increase in size gradually over years. Dissemination to extracutaneous sites is uncommon. In two studies, 18 of 171 (10 percent) and 26 of 243 (10.7 percent) patients developed extracutaneous disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15464/abstract/7,9\">",
"     7,9",
"    </a>",
"    ]. Retrospective analyses suggest that following initial treatment with radiation therapy, up to 30 percent of patients will relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15464/abstract/37\">",
"     37",
"    </a>",
"    ]. PCFCL have an excellent prognosis with reported five-year survival rates of approximately 95 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15464/abstract/3,7-9,27,34\">",
"     3,7-9,27,34",
"    </a>",
"    ]. Growth pattern (follicular, follicular and diffuse, or diffuse), number of blast cells, the extent of skin lesions (solitary, regional, or multifocal), the presence or absence of t(14;18) or bcl-2 expression have no significant effect on survival. However, PCFCL presenting with skin lesions on the leg are reported to have a more unfavorable prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15464/abstract/6,41\">",
"     6,41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary cutaneous B cell lymphoma (PCBCL) refers to those cases of B cell lymphoma that present in the skin when there is no evidence of extracutaneous disease at the time of diagnosis and after the completion of an initial staging evaluation. Primary cutaneous follicle center lymphoma (PCFCL) is the most common PCBCL. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients typically present with firm erythematous, painless, nonpruritic papules, nodules or plaques with a predilection for the head, neck, and trunk. The lesions are generally smooth and do not typically ulcerate. Disseminated lesions are rare. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of PCFCL requires a representative biopsy of involved skin and the exclusion of non-cutaneous disease in the appropriate clinical setting. A typical biopsy of PFCL demonstrates an epidermis-sparing B cell infiltrate comprised of centrocytes and centroblasts with a follicular or diffuse pattern. B cell lineage is confirmed by the presence of CD20 or CD79a and the absence of CD3. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Pathologic features'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The staging evaluation both confirms the diagnosis by excluding involvement of other sites and provides information to guide treatment. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Staging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      PCFCL is a rare disorder; accordingly, large trials are lacking. The published data regarding treatment consist entirely of retrospective reviews and anecdotal reports. In general, our treatment approach depends upon the number of lesions, their location, and the presence of symptoms attributable to the lesions (eg, pruritus):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients with focal disease (a solitary lesion or lesions that can be contained in one radiation field), we suggest treatment with radiation therapy, rather than chemotherapy, surgical excision, or observation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). At least 30 Gy of radiation should be delivered to a field that includes a margin of at least 1 to 1.5 cm of uninvolved skin. Surgical excision or observation is an acceptable alternative for lesions that are not amenable to radiation therapy (eg, in a location at which radiation toxicity is increased). The choice between these two alternatives depends upon the morbidity associated with excision. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with a few scattered lesions not able to fit in one radiation field, we suggest treatment with either radiation therapy to all visible lesions or initial observation rather than excision or multiagent chemotherapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The choice to irradiate or not depends upon the sites involved and expected toxicity of radiation to the area and the presence or absence of symptoms. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with extensive, diffuse disease, we suggest treatment with single agent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      rather than observation, radiation therapy, or multiagent chemotherapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We reserve combination chemotherapy for the rare case with extremely extensive, symptomatic disease or those who fail to respond to initial rituximab. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Approximately 30 percent of patients initially treated with radiation therapy will relapse. Most relapses are confined to the skin and are treated with the same modalities as initial therapy. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Treatment at relapse'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Swerdlow SH, Campo E, Harris NL, et al. (Eds), IARC Press, Lyon 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15464/abstract/2\">",
"      Burg G, Kerl H, Przybilla B, Braun-Falco O. Some statistical data, diagnosis, and staging of cutaneous B-cell lymphomas. J Dermatol Surg Oncol 1984; 10:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15464/abstract/3\">",
"      Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105:3768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15464/abstract/4\">",
"      Dores GM, Anderson WF, Devesa SS. Cutaneous lymphomas reported to the National Cancer Institute's surveillance, epidemiology, and end results program: applying the new WHO-European Organisation for Research and Treatment of Cancer classification system. J Clin Oncol 2005; 23:7246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15464/abstract/5\">",
"      Willemze R, Kerl H, Sterry W, et al. EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood 1997; 90:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15464/abstract/6\">",
"      Fink-Puches R, Zenahlik P, B&auml;ck B, et al. Primary cutaneous lymphomas: applicability of current classification schemes (European Organization for Research and Treatment of Cancer, World Health Organization) based on clinicopathologic features observed in a large group of patients. Blood 2002; 99:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15464/abstract/7\">",
"      Senff NJ, Hoefnagel JJ, Jansen PM, et al. Reclassification of 300 primary cutaneous B-Cell lymphomas according to the new WHO-EORTC classification for cutaneous lymphomas: comparison with previous classifications and identification of prognostic markers. J Clin Oncol 2007; 25:1581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15464/abstract/8\">",
"      Mirza I, Macpherson N, Paproski S, et al. Primary cutaneous follicular lymphoma: an assessment of clinical, histopathologic, immunophenotypic, and molecular features. J Clin Oncol 2002; 20:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15464/abstract/9\">",
"      Zinzani PL, Quaglino P, Pimpinelli N, et al. Prognostic factors in primary cutaneous B-cell lymphoma: the Italian Study Group for Cutaneous Lymphomas. J Clin Oncol 2006; 24:1376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15464/abstract/10\">",
"      Bradford PT, Devesa SS, Anderson WF, Toro JR. Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. Blood 2009; 113:5064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15464/abstract/11\">",
"      Franco R, Fernandez-Vazquez A, Rodriguez-Peralto JL, et al. Cutaneous follicular B-cell lymphoma: description of a series of 18 cases. Am J Surg Pathol 2001; 25:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15464/abstract/12\">",
"      Massone C, Fink-Puches R, Laimer M, et al. Miliary and agminated-type primary cutaneous follicle center lymphoma: report of 18 cases. J Am Acad Dermatol 2011; 65:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15464/abstract/13\">",
"      Cerroni L, Kerl H. Primary cutaneous follicle center cell lymphoma. Leuk Lymphoma 2001; 42:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15464/abstract/14\">",
"      Pimpinelli N, Santucci M, Mori M, et al. Primary cutaneous B-cell lymphoma: a clinically homogeneous entity? J Am Acad Dermatol 1997; 37:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15464/abstract/15\">",
"      Fung MA, Murphy MJ, Hoss DM, Grant-Kels JM. Practical evaluation and management of cutaneous lymphoma. J Am Acad Dermatol 2002; 46:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15464/abstract/16\">",
"      Watabe H, Kawakami T, Soma Y, et al. Primary cutaneous T-cell-rich B-cell lymphoma in a zosteriform distribution associated with Epstein-Barr virus infection. J Dermatol 2002; 29:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15464/abstract/17\">",
"      Marzano AV, Berti E, Alessi E. Primary cutaneous B-cell lymphoma with a dermatomal distribution. J Am Acad Dermatol 1999; 41:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15464/abstract/18\">",
"      Gulia A, Saggini A, Wiesner T, et al. Clinicopathologic features of early lesions of primary cutaneous follicle center lymphoma, diffuse type: implications for early diagnosis and treatment. J Am Acad Dermatol 2011; 65:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15464/abstract/19\">",
"      Bergman R, Kurtin PJ, Gibson LE, et al. Clinicopathologic, immunophenotypic, and molecular characterization of primary cutaneous follicular B-cell lymphoma. Arch Dermatol 2001; 137:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15464/abstract/20\">",
"      Burg G, Kempf W, Haeffner AC, et al. Cutaneous lymphomas. Curr Probl Dermatol 1997; 9:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15464/abstract/21\">",
"      Grange F, Hedelin G, Joly P, et al. Prognostic factors in primary cutaneous lymphomas other than mycosis fungoides and the S&eacute;zary syndrome. The French Study Group on Cutaneous Lymphomas. Blood 1999; 93:3637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15464/abstract/22\">",
"      Willemze R, Meijer CJ, Sentis HJ, et al. Primary cutaneous large cell lymphomas of follicular center cell origin. A clinical follow-up study of nineteen patients. J Am Acad Dermatol 1987; 16:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15464/abstract/23\">",
"      Santucci M, Pimpinelli N, Arganini L. Primary cutaneous B-cell lymphoma: a unique type of low-grade lymphoma. Clinicopathologic and immunologic study of 83 cases. Cancer 1991; 67:2311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15464/abstract/24\">",
"      de Leval L, Harris NL, Longtine J, et al. Cutaneous b-cell lymphomas of follicular and marginal zone types: use of Bcl-6, CD10, Bcl-2, and CD21 in differential diagnosis and classification. Am J Surg Pathol 2001; 25:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15464/abstract/25\">",
"      Hoefnagel JJ, Dijkman R, Basso K, et al. Distinct types of primary cutaneous large B-cell lymphoma identified by gene expression profiling. Blood 2005; 105:3671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15464/abstract/26\">",
"      Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15464/abstract/27\">",
"      Goodlad JR, Krajewski AS, Batstone PJ, et al. Primary cutaneous follicular lymphoma: a clinicopathologic and molecular study of 16 cases in support of a distinct entity. Am J Surg Pathol 2002; 26:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15464/abstract/28\">",
"      Child FJ, Russell-Jones R, Woolford AJ, et al. Absence of the t(14;18) chromosomal translocation in primary cutaneous B-cell lymphoma. Br J Dermatol 2001; 144:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15464/abstract/29\">",
"      Grange F, Petrella T, Beylot-Barry M, et al. Bcl-2 protein expression is the strongest independent prognostic factor of survival in primary cutaneous large B-cell lymphomas. Blood 2004; 103:3662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15464/abstract/30\">",
"      Dijkman R, Tensen CP, Jordanova ES, et al. Array-based comparative genomic hybridization analysis reveals recurrent chromosomal alterations and prognostic parameters in primary cutaneous large B-cell lymphoma. J Clin Oncol 2006; 24:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15464/abstract/31\">",
"      Sterry W, Kr&uuml;ger GR, Steigleder GK. Skin involvement of malignant B-cell lymphomas. J Dermatol Surg Oncol 1984; 10:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15464/abstract/32\">",
"      Magro C, Crowson AN, Porcu P, Nuovo GJ. Automated kappa and lambda light chain mRNA expression for the assessment of B-cell clonality in cutaneous B-cell infiltrates: its utility and diagnostic application. J Cutan Pathol 2003; 30:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15464/abstract/33\">",
"      Kim YH, Willemze R, Pimpinelli N, et al. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15464/abstract/34\">",
"      Grange F, Bekkenk MW, Wechsler J, et al. Prognostic factors in primary cutaneous large B-cell lymphomas: a European multicenter study. J Clin Oncol 2001; 19:3602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15464/abstract/35\">",
"      Cerroni L, Arzberger E, P&uuml;tz B, et al. Primary cutaneous follicle center cell lymphoma with follicular growth pattern. Blood 2000; 95:3922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15464/abstract/36\">",
"      Fern&aacute;ndez de Larrea C, Mart&iacute;nez-Pozo A, Mercadal S, et al. Initial features and outcome of cutaneous and non-cutaneous primary extranodal follicular lymphoma. Br J Haematol 2011; 153:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15464/abstract/37\">",
"      Senff NJ, Noordijk EM, Kim YH, et al. European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. Blood 2008; 112:1600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15464/abstract/38\">",
"      Neelis KJ, Schimmel EC, Vermeer MH, et al. Low-dose palliative radiotherapy for cutaneous B- and T-cell lymphomas. Int J Radiat Oncol Biol Phys 2009; 74:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15464/abstract/39\">",
"      Pe&ntilde;ate Y, Hern&aacute;ndez-Mach&iacute;n B, P&eacute;rez-M&eacute;ndez LI, et al. Intralesional rituximab in the treatment of indolent primary cutaneous B-cell lymphomas: an epidemiological observational multicentre study. The Spanish Working Group on Cutaneous Lymphoma. Br J Dermatol 2012; 167:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15464/abstract/40\">",
"      Terhorst D, Mestel DS, Humme D, et al. Evaluation of different methods in the follow-up of patients with indolent types of primary cutaneous lymphomas. Br J Dermatol 2012; 166:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15464/abstract/41\">",
"      Kodama K, Massone C, Chott A, et al. Primary cutaneous large B-cell lymphomas: clinicopathologic features, classification, and prognostic factors in a large series of patients. Blood 2005; 106:2491.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4718 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-B86BBD9DD2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_6_15464=[""].join("\n");
var outline_f15_6_15464=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PATHOLOGIC FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Morphology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Immunophenotype",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Genetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Systemic lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Reactive infiltrate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Primary cutaneous diffuse large B cell lymphoma, leg type",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Primary cutaneous marginal zone lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Cutaneous T cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Intravascular lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      STAGING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      ASSESSING DISEASE RESPONSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      TREATMENT AT RELAPSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21004020\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4718\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4718|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/24/2435\" title=\"picture 1A\">",
"      PCFCL chest",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/16/21765\" title=\"picture 1B\">",
"      PCFCL scalp",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4718|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/56/11149\" title=\"table 1\">",
"      Staging of cutaneous lymphoma other than MF SS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/32/4618?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/46/25322?source=related_link\">",
"      Clinical manifestations, pathologic features, diagnosis, and prognosis of follicular lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15658?source=related_link\">",
"      Initial evaluation and staging of non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/12/13511?source=related_link\">",
"      Intravascular large cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/49/26391?source=related_link\">",
"      Primary cutaneous large B cell lymphoma, leg type",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/9/26776?source=related_link\">",
"      Primary cutaneous marginal zone lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29127?source=related_link\">",
"      Prognosis of diffuse large B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21785?source=related_link\">",
"      Radiation-related risks of imaging studies",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_6_15465="Overview of the etiology and evaluation of vaginal bleeding in pregnant women";
var content_f15_6_15465=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of the etiology and evaluation of vaginal bleeding in pregnant women",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/6/15465/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/6/15465/contributors\">",
"     Errol R Norwitz, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/6/15465/contributors\">",
"     Joong Shin Park, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/6/15465/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/6/15465/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/6/15465/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/6/15465/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/6/15465/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 8, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaginal bleeding is a common event at all stages of pregnancy. The source is virtually always maternal, rather than fetal. Bleeding may result from disruption of decidual blood vessels or from discrete cervical or vaginal lesions. The clinician typically makes a provisional clinical diagnosis based upon the patient's gestational age and the character of her bleeding (light or heavy, associated with pain or painless, intermittent or constant). Laboratory and imaging tests are then used to confirm or revise the initial diagnosis.",
"   </p>",
"   <p>",
"    An overview of the etiology and evaluation of vaginal bleeding in pregnant women will be reviewed here. Specific causes of bleeding and their management are discussed in detail separately. (See individual topic reviews on each subject).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     FIRST TRIMESTER BLEEDING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaginal bleeding is common in the first trimester, occurring in 20 to 40 percent of pregnant women. It may be any combination of light or heavy, intermittent or constant, painless or painful. The four major sources of bleeding in early pregnancy are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ectopic pregnancy",
"     </li>",
"     <li>",
"      Miscarriage (threatened, inevitable, incomplete, complete)",
"     </li>",
"     <li>",
"      Implantation of the pregnancy",
"     </li>",
"     <li>",
"      Cervical, vaginal, or uterine pathology (eg, polyps,",
"      <span class=\"nowrap\">",
"       inflammation/infection,",
"      </span>",
"      trophoblastic disease)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Bleeding related to miscarriage is the most common cause of first trimester bleeding. Ectopic pregnancy is relatively common and the most serious etiology as rupture of the extrauterine pregnancy is a life threatening complication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The exact etiology of uterine bleeding in the first trimester often cannot be determined; the goal of the evaluation is to make a definitive diagnosis when possible and exclude the presence of serious pathology in the remaining cases. Ectopic pregnancy is particularly important to exclude since it can be life-threatening. Thus, the first step in evaluation is to determine whether the patient has had an ultrasound examination, as well as the results of the test. Prior documentation that the pregnancy is intrauterine immediately narrows the differential diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The extent of bleeding should be determined: is the woman passing blood clots or is the blood soaking through her clothes? Does she feel lightheaded? Does she have significant pelvic pain or cramping? Has she passed any tissue? If she answers yes to these questions, then ectopic pregnancy and miscarriage are more likely diagnoses than implantation bleeding or cervicovaginal disease (eg, polyps, cervicitis, cancer). On the other hand, it is important to remember that the presence of only light, intermittent, painless bleeding does not exclude the possibility of a life-threatening underlying disorder, such as ectopic pregnancy.",
"   </p>",
"   <p>",
"    What is the patient's medical history? A past history of ectopic pregnancy or risk factors for ectopic pregnancy (eg, history of pelvic inflammatory disease, presence of an intrauterine contraceptive device, adnexal surgery) increases the probability of this disorder. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/15/21752?source=see_link\">",
"     \"Incidence, risk factors, and pathology of ectopic pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A history of two or more consecutive miscarriages or a condition associated with miscarriage (eg, parental chromosomal translocation, maternal antiphospholipid syndrome, uterine anomaly) suggests bleeding may be related to impending pregnancy loss. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/23/19834?source=see_link\">",
"     \"Spontaneous abortion: Risk factors, etiology, clinical manifestations, and diagnostic evaluation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Orthostatic changes in blood pressure or pulse are indicative of severe blood loss.",
"   </p>",
"   <p>",
"    Any tissue the patient has passed should be examined. Patients may mistake blood clot for the products of conception. If the tissue represents a partial or complete miscarriage, the fetal membranes, fronds indicative of placental villi, or an intact fetus should be visible upon careful examination. Visualization of villi can be facilitated by floating the products of conception in water (",
"    <a class=\"graphic graphic_picture graphicRef78715 graphicRef61424 \" href=\"UTD.htm?39/8/40068\">",
"     picture 1A-B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The patient's abdomen should be examined before performing an internal examination. It is best to begin by examining the quadrant where the patient is experiencing the least pain. Gentle percussion is preferred to deep palpation since it causes less pain and guarding. Midline pain is more consistent with miscarriage, while lateral pain is more consistent with ectopic pregnancy. Nongynecologic causes of pain also to be considered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/44/36554?source=see_link\">",
"     \"Approach to abdominal pain and the acute abdomen in pregnant and postpartum women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinician should determine whether uterine size is appropriate for the estimated gestational age. The size - gestational age correlation is learned by experience and is often described in terms of fruit (eg, 6 to 8 week size = small pear, 8 to 10 week size = orange, 10 to 12 week size = grapefruit). The uterus remains a pelvic organ until approximately 12 weeks of gestation, when it becomes sufficiently large to palpate transabdominally just above the symphysis pubis. The normal uterus is nontender, smooth, and firm.",
"   </p>",
"   <p>",
"    If the pregnancy is at or beyond 10 to 12 weeks of gestation, a handheld Doppler device can be used to check the fetal heart beat. The fetal heart rate can be easily distinguished from the maternal heart rate since the fetal heart rate is typically in the range of 110 to 160 beats per minute [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15465/abstract/1\">",
"     1",
"    </a>",
"    ]. Doppler confirmation of fetal cardiac activity is reassuring, as it indicates bleeding is not related to fetal demise and unlikely to be related to an ectopic pregnancy. On the other hand, loss of a previously detected fetal heart beat should raise suspicion that fetal demise has occurred. However, inability to detect fetal heart motion by Doppler is subject to physician error, particularly in the first trimester.",
"   </p>",
"   <p>",
"    After the abdominal examination, the patient is placed in the lithotomy position. The external genitalia are examined to assess the volume and source of bleeding and then a speculum is inserted into the vagina. If blood clots, products of conception, or both are present, they can be removed with gauze sponges on a sponge forceps. This tissue is examined as described above and, by convention, sent for pathologic examination to confirm the presence of products of conception and to exclude gestational trophoblastic disease. The utility of routine histopathological examination is questionable, as it rarely suggests the underlying cause of the pregnancy failure or establishes a diagnosis of gestational trophoblastic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15465/abstract/2\">",
"     2",
"    </a>",
"    ]. However, pathologists can sometimes diagnose entities that are the probable cause of the loss or associated with recurrence. These include massive chronic intervillositis, massive intervillous fibrin deposition, maternal vasculitis, findings suggestive of some chromosomal anomalies (eg, triploidy, some trisomies), and septic abortion.",
"   </p>",
"   <p>",
"    Speculum examination may reveal a source of bleeding unrelated to pregnancy; in such cases, further evaluation depends upon the nature of the abnormality:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vaginal laceration (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/2/44071?source=see_link\">",
"       \"Evaluation and management of lower genital tract trauma in women\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Vaginal neoplasm (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31208?source=see_link\">",
"       \"Vaginal cancer\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Vaginal warts (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/38/23144?source=see_link\">",
"       \"Condylomata acuminata (anogenital warts)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Vaginal discharge (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/49/36633?source=see_link\">",
"       \"Approach to women with symptoms of vaginitis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Cervical polyps, fibroids, ectropion (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23048?source=see_link\">",
"       \"Congenital cervical anomalies and benign cervical lesions\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Mucopurulent cervical discharge or friability at the endocervical os (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/4/64?source=see_link\">",
"       \"Acute cervicitis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Cervical neoplasm (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28537?source=see_link\">",
"       \"Invasive cervical cancer: Epidemiology, risk factors, clinical manifestations, and diagnosis\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Visualization of the cervical os helps to distinguish between a threatened and an",
"    <span class=\"nowrap\">",
"     impending/inevitable",
"    </span>",
"    miscarriage. Direct visualization of the gestational sac in a dilated cervix is generally sufficient to diagnose an",
"    <span class=\"nowrap\">",
"     impending/inevitable",
"    </span>",
"    miscarriage clinically. The cervix will also be open after a recent incomplete or complete miscarriage. Ultrasound can provide additional information in these cases, such as whether or not there are retained products of conception, or the unexpected presence of a twin pregnancy with a second viable gestational sac.",
"   </p>",
"   <p>",
"    A closed cervix is consistent with a threatened miscarriage, but not diagnostic. If the cervix appears closed and there are no obvious bleeding lesions, the speculum is removed and a bimanual pelvic examination is performed. With an ectopic pregnancy, findings on pelvic examination may include adnexal, cervical motion, or abdominal tenderness; an adnexal mass; and mild uterine enlargement. However, the physical examination is often unremarkable in a woman with a small, unruptured ectopic pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1178?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and management of ectopic pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Uterine size larger than expected for dates suggests a multiple gestation, possibly with miscarriage of one of the multiples, gestational trophoblastic disease (molar pregnancy), or other uterine pathology (fibroids can cause an irregularly enlarged uterus). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/46/40682?source=see_link\">",
"     \"Twin pregnancy: Prenatal issues\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/11/24761?source=see_link\">",
"     \"Gestational trophoblastic disease: Epidemiology, clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/17/6426?source=see_link\">",
"     \"Epidemiology, clinical manifestations, diagnosis, and natural history of uterine leiomyomas (fibroids)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One review of data from observational studies concluded that ultrasound examination and human chorionic gonadotropin (hCG) concentration (both discussed below) could replace pelvic examination in the initial evaluation of patients with early pregnancy bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15465/abstract/3\">",
"     3",
"    </a>",
"    ]. However, some diagnoses will be missed with this approach (eg, bleeding from cervical or vaginal lesions), this combination of tests may not distinguish between a complete miscarriage and an ectopic pregnancy (both will have an empty uterus and positive hCG), and the additional cost of the tests can be avoided in some patients. For example, in bleeding patients in whom sonography has previously confirmed a viable singleton intrauterine pregnancy, another examination is not necessary to exclude ectopic pregnancy or to confirm fetal viability if fetal heart motion can be detected by a handheld Doppler device. Additionally, there is no value in checking human chorionic gonadotropin (hCG) concentration once the presence of an intrauterine pregnancy has been established sonographically.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Ultrasonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transvaginal ultrasonography is the cornerstone of the evaluation of bleeding in early pregnancy. It is most useful in bleeding patients with a positive pregnancy test in whom an intrauterine pregnancy has not been previously confirmed by imaging studies. In these women, ultrasound examination is performed to determine whether the pregnancy is intrauterine or extrauterine (ectopic) and, if intrauterine, whether the pregnancy is viable (fetal cardiac activity present) or nonviable.",
"   </p>",
"   <p>",
"    It is important to note that the absence of an intrauterine gestational sac is highly suggestive of ectopic pregnancy if more than 5.5 to 6 weeks have elapsed since the first day of the patient's last menstrual period. At earlier gestational ages, however, an intrauterine pregnancy may be present, but not yet identifiable, by ultrasound. In these cases, sonographic findings are correlated with human chorionic gonadotropin (hCG) levels. The use of sonography and hCG in the differential diagnosis of intrauterine versus extrauterine pregnancy and viable versus nonviable intrauterine pregnancy is described briefly below (see",
"    <a class=\"local\" href=\"#H7\">",
"     'Laboratory tests'",
"    </a>",
"    below) and in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/23/19834?source=see_link\">",
"     \"Spontaneous abortion: Risk factors, etiology, clinical manifestations, and diagnostic evaluation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1178?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and management of ectopic pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rarely, ultrasound examination reveals unusual causes of uterine bleeding, such as gestational trophoblastic disease or loss of one fetus from a multiple gestation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/11/24761?source=see_link\">",
"     \"Gestational trophoblastic disease: Epidemiology, clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/46/40682?source=see_link&amp;anchor=H5#H5\">",
"     \"Twin pregnancy: Prenatal issues\", section on 'Early and late loss'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In bleeding patients in whom sonography has previously confirmed a viable singleton intrauterine pregnancy, another examination is not necessary to confirm fetal viability if fetal heart motion can be detected by a handheld Doppler device.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Laboratory tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no role for monitoring human chorionic gonadotropin (hCG) concentration once the presence of an intrauterine pregnancy has been established sonographically. Serial measurements of hCG are helpful during the first six weeks of pregnancy if ultrasonography is nondiagnostic, ie, the site and viability of the pregnancy are not revealed. In this setting:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Falling beta-hCG concentrations are consistent with a nonviable intrauterine pregnancy or involuting ectopic pregnancy, but do not indicate whether the pregnancy is intrauterine or ectopic.",
"     </li>",
"     <li>",
"      Appropriately rising hCG levels are most consistent with a viable intrauterine pregnancy (85 percent of viable pregnancies display a rise in hCG greater than 66 percent over 48 hours), but some ectopic pregnancies also display this pattern.",
"     </li>",
"     <li>",
"      hCG levels that have plateaued or are rising slowly suggest an ectopic pregnancy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The pattern of hCG change in normal and abnormal pregnancies and its correlation with ultrasound findings are discussed in detail separately, and summarized below. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1178?source=see_link&amp;anchor=H9#H9\">",
"     \"Clinical manifestations, diagnosis, and management of ectopic pregnancy\", section on 'Human chorionic gonadotropin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other hormone assays (eg, progesterone, estrogen, inhibin A, PAPP-A) are less useful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Differential diagnosis and management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The information gleaned from the above evaluation is used to determine a diagnosis and plan of management. Women with significant first trimester vaginal bleeding (ie, menses-like) should have a red blood cell antibody screen checked. Those who are Rh(D) negative are given anti-D immunoglobulin to protect against Rh(D) isoimmunization, unless the vaginal bleeding is clearly due to a nonplacental, nonfetal source, such as a vaginal laceration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40648?source=see_link\">",
"     \"Prevention of Rh(D) alloimmunization\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Ectopic pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with a history of ectopic pregnancy and early pregnancy bleeding and pain are assumed to have recurrent ectopic pregnancy until this diagnosis has been excluded by laboratory and imaging studies.",
"   </p>",
"   <p>",
"    In the hands of an experienced ultrasonographer, absence of an intrauterine pregnancy on transvaginal ultrasound examination when the hCG concentration is greater than 1000 to 2000",
"    <span class=\"nowrap\">",
"     IU/L",
"    </span>",
"    (greater than 6000",
"    <span class=\"nowrap\">",
"     IU/L",
"    </span>",
"    for transabdominal ultrasound) strongly suggests ectopic pregnancy (with less experienced sonographers the threshold may be higher, 2000 to 4000",
"    <span class=\"nowrap\">",
"     IU/L",
"    </span>",
"    ). An adnexal mass may or may not be seen. The presence of hemodynamic instability and a tender abdomen suggests the ectopic pregnancy has ruptured.",
"   </p>",
"   <p>",
"    Diagnosis of intrauterine (viable or nonviable) versus extrauterine pregnancy at hCG concentrations below 1500",
"    <span class=\"nowrap\">",
"     IU/L",
"    </span>",
"    is complicated and discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1178?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and management of ectopic pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Management of ectopic pregnancy is generally medical (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    therapy) or surgical. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/49/27417?source=see_link\">",
"     \"Methotrexate treatment of tubal and interstitial ectopic pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/53/5976?source=see_link\">",
"     \"Surgical treatment of ectopic pregnancy and prognosis for subsequent fertility\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Expectant management can be dangerous for the mother, but may be possible in rare cases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/60/21444?source=see_link\">",
"     \"Expectant management of ectopic pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Even if an intrauterine pregnancy is diagnosed, the possibility of heterotopic pregnancy should be kept in mind, even though rare. This is particularly important in women who underwent in vitro fertilization since these patients are at increased risk of this pregnancy complication. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/4/16457?source=see_link\">",
"     \"Abdominal pregnancy, cesarean scar pregnancy, and heterotopic pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Threatened miscarriage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uterine bleeding in the presence of a closed cervix and sonographic visualization of an intrauterine pregnancy with detectable fetal cardiac activity is diagnostic of threatened miscarriage. The term \"threatened\" is used to describe these cases because miscarriage does not always follow uterine bleeding in early pregnancy, even after repeated episodes or large amounts of bleeding. In fact, 90 to 96 percent of pregnancies with both fetal cardiac activity and vaginal bleeding at 7 to 11 weeks of gestation do not miscarry; the higher success rate is associated with bleeding at the later end of the gestational age range [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15465/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Uterine bleeding in these cases is likely due to disruption of decidual vessels at the maternal-fetal interface. These separations generally cannot be visualized by ultrasound, but sometimes appear as a subchorionic hematoma. Management is expectant. The diagnosis and outcome of subchorionic hematoma are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/23/19834?source=see_link&amp;anchor=H35#H35\">",
"     \"Spontaneous abortion: Risk factors, etiology, clinical manifestations, and diagnostic evaluation\", section on 'Findings potentially predictive of pregnancy loss'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Inevitable miscarriage",
"    </span>",
"    &nbsp;&mdash;&nbsp;When miscarriage is inevitable, the cervix is dilated, uterine bleeding is increasing, and painful uterine",
"    <span class=\"nowrap\">",
"     cramps/contractions",
"    </span>",
"    are present. The gestational tissue often can be felt or seen through the cervical os; passage of this tissue typically occurs within a short time. Management may be expectant, or a medical or surgical intervention to complete the miscarriage can be undertaken. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/23/19834?source=see_link\">",
"     \"Spontaneous abortion: Risk factors, etiology, clinical manifestations, and diagnostic evaluation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/49/2841?source=see_link\">",
"     \"Spontaneous abortion: Management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Complete and incomplete miscarriage",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete miscarriage &mdash; When a miscarriage occurs before 12 weeks of gestation, it is common for the entire contents of the uterus to be expelled, thereby resulting in a complete miscarriage. If this has occurred, the uterus is small on physical examination and well contracted with an open or closed cervix, scant vaginal bleeding, and only mild cramping. Ultrasound will reveal an empty uterus and no extrauterine gestation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A complete miscarriage can be distinguished from an ectopic pregnancy by examining the tissue that was passed to confirm products of conception, by demonstrating falling rather than rising or plateaued hCG levels, and by patient description of diminishing bleeding and pain. No further intervention is needed for complete miscarriage if chorionic villi are identified by pathologic examination of the products of conception. However, if no villi are identified or no specimens are available for pathologic examination, then serum hCG levels should be followed serially until the level is undetectable. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/23/19834?source=see_link\">",
"     \"Spontaneous abortion: Risk factors, etiology, clinical manifestations, and diagnostic evaluation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/49/2841?source=see_link\">",
"     \"Spontaneous abortion: Management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Incomplete miscarriage &mdash; After 12 weeks of gestation, the membranes may rupture and the fetus may be passed, but significant amounts of placental tissue can be retained, resulting in an incomplete miscarriage. On examination, the cervical os is open, gestational tissue may be observed in the cervix, and the uterine size is smaller than expected for gestational age, but not well contracted. The amount of bleeding varies, but can be severe enough to cause hypovolemic shock. Painful",
"      <span class=\"nowrap\">",
"       cramps/contractions",
"      </span>",
"      are often present. Ultrasound reveals tissue in the uterus. Medical or surgical evacuation is generally performed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Missed abortion",
"    </span>",
"    &nbsp;&mdash;&nbsp;A missed abortion (also called a delayed miscarriage) refers to in-utero death of the embryo or fetus prior to the 20th week of gestation, with retention of the pregnancy for a prolonged period of time. Women may notice that symptoms associated with early pregnancy (eg, nausea, breast tenderness) have abated and they don't \"feel pregnant\" anymore. Vaginal bleeding may occur. The cervix usually remains closed. Ultrasound reveals an intrauterine gestational sac with or without a fetal pole, but no fetal cardiac activity. Management may be expectant or a medical or surgical intervention to complete the miscarriage can be undertaken. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/23/19834?source=see_link\">",
"     \"Spontaneous abortion: Risk factors, etiology, clinical manifestations, and diagnostic evaluation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Vanishing twin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term \"vanishing twin\" has been used to describe a singleton pregnancy which results from very early loss of one member of a multiple gestation. Vanishing twins are often the product of assisted reproduction techniques and can be associated with vaginal bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15465/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/6/2154?source=see_link&amp;anchor=H4#H4\">",
"     \"Pregnancy outcome after assisted reproductive technology\", section on 'Early loss'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/46/40682?source=see_link&amp;anchor=H5#H5\">",
"     \"Twin pregnancy: Prenatal issues\", section on 'Early and late loss'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Vaginitis, trauma, cancer, warts, polyps, fibroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;These conditions are diagnosed by visual inspection, with ancillary tests as indicated (eg, wet mount and pH of vaginal discharge, cervical cytology",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    biopsy of mass lesions, ultrasound examination of fibroids).",
"   </p>",
"   <p>",
"    Management of bleeding related to these conditions depends upon the specific condition. (See individual topic reviews on each subject).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Ectropion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cervical ectropion (columnar epithelium exposed to the vaginal milieu by eversion of the endocervix) is a common and normal finding in pregnancy. The exposed columnar epithelium is prone to light bleeding when touched, such as during coitus, insertion of a speculum, bimanual examination, or when a cervical specimen is obtained for cytology or culture. Therapy is unnecessary. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23048?source=see_link&amp;anchor=H10#H10\">",
"     \"Congenital cervical anomalies and benign cervical lesions\", section on 'Ectropion'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Physiologic or implantation bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;This is a diagnosis of exclusion. It is characterized by a small amount of spotting or bleeding approximately 10 to 14 days after fertilization (at the time of the missed menstrual period), and is presumed to be related to implantation of the fertilized egg in the decidua (ie, lining of the uterus) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15465/abstract/7\">",
"     7",
"    </a>",
"    ], although this hypothesis has been questioned [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15465/abstract/8\">",
"     8",
"    </a>",
"    ]. No intervention is indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies consistently show an association between first trimester bleeding and adverse outcome (eg, miscarriage, preterm birth, premature rupture of membranes, fetal growth restriction) later in pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15465/abstract/8-20\">",
"     8-20",
"    </a>",
"    ]. The prognosis is best when bleeding is light and limited to early pregnancy, ie, less than 6 weeks of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15465/abstract/8,17\">",
"     8,17",
"    </a>",
"    ]. The prognosis worsens when bleeding is heavy or extends into the second trimester [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15465/abstract/12-16\">",
"     12-16",
"    </a>",
"    ]. These relationships are illustrated by the following examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 550 women followed prospectively from the time of their positive pregnancy test, 117 (21 percent) had bleeding prior to 20 weeks of gestation and 67 miscarried (12 percent, or about one-half of those with bleeding) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/6/15465/abstract/21\">",
"       21",
"      </a>",
"      ]. Fourteen of 18 pregnancies with heavy bleeding (eg, clots) and moderate pain miscarried (78 percent).",
"     </li>",
"     <li>",
"      In one large prospective series in which all subjects had a viable pregnancy at enrollment at 10 to 14 weeks, the frequency of preterm delivery with no, light, or heavy first trimester bleeding was about 6, 9, and 14 percent, respectively, and the frequency of spontaneous loss before 24 weeks of gestation was 0.4, 1, and 2 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?15/6/15465/abstract/12\">",
"       12",
"      </a>",
"      ]. Because these subjects were enrolled late in the first trimester and with sonographically confirmed fetal viability, women with very early bleeding and miscarriage had already been excluded.",
"     </li>",
"     <li>",
"      In a third series, vaginal bleeding occurring in more than one trimester was associated with a greater than seven-fold increased risk of preterm premature rupture of membranes (OR 7.4; 95% CI 2.2-25.6) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/6/15465/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A retrospective registry-based study including over one million women found that, compared to women without bleeding, first trimester bleeding significantly increased the risk of preterm birth at 28 to 31 weeks (0.9 versus 0.3 percent; OR 2.98, 95% CI 2.50-3.54) and at 32 to 36 weeks (6.1 versus 3.6 percent; OR 1.65, 95% CI 1.57-1.77) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/6/15465/abstract/18\">",
"       18",
"      </a>",
"      ]. First trimester bleeding was also associated with a significant increase in risk of bleeding and preterm birth in the subsequent pregnancy. A history of first trimester bleeding in the first pregnancy increased the incidence of bleeding in the second pregnancy from 2.2 percent to 8.2 percent (OR 4.05; 95% CI 3.78-4.34) and increased the incidence of preterm delivery from 2.7 percent to 4.8 percent (OR 1.83; 95% CI 1.67-2.00).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    No change in pregnancy management is indicated for women with first trimester bleeding. There are no effective interventions, but women can be reassured of the low likelihood of adverse outcome. In particular, bedrest is unnecessary and will not affect outcome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/3/35898?source=see_link&amp;anchor=H9#H9\">",
"     \"Risk factors for preterm labor and delivery\", section on 'Vaginal bleeding'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SECOND AND THIRD TRIMESTER BLEEDING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaginal bleeding is less common in the second and third trimesters. The major causes of bleeding at these times are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Bloody show associated with cervical insufficiency or labor",
"     </li>",
"     <li>",
"      Placenta previa",
"     </li>",
"     <li>",
"      Abruptio placenta",
"     </li>",
"     <li>",
"      Uterine rupture",
"     </li>",
"     <li>",
"      Vasa previa",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Prior to 20 weeks of gestation",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation of pregnant women with vaginal bleeding prior to 20 weeks is similar to that in the first trimester (see above); however, ectopic pregnancy is less of a concern because over 95 percent of ectopic pregnancies occur in the fallopian tube and virtually all tubal ectopic pregnancies will have been diagnosed by this time. Although abdominal, heterotopic, cervical, cornual, and cesarean scar ectopic pregnancies often present at more advanced gestations than tubal ectopics, these types of ectopic pregnancy are rare.",
"   </p>",
"   <p>",
"    The first step in the evaluation is to determine the extent of bleeding and whether bleeding is accompanied by pain. The presence of only light, intermittent, painless bleeding suggests bloody show from cervical insufficiency, a small marginal placental separation, or a cervical or vaginal lesion (eg, polyp, infection, cancer). Heavier bleeding, particularly when associated with pain, is more consistent with impending miscarriage or a larger placental separation (ie, abruption).",
"   </p>",
"   <p>",
"    As discussed above, loss of a previously detected fetal heart beat should raise suspicion that fetal demise has occurred, but inability to detect the fetal heart by Doppler is subject to physician error and should always be confirmed by ultrasound examination. On the other hand, Doppler confirmation of fetal cardiac activity is reassuring.",
"   </p>",
"   <p>",
"    An abdominal examination is performed to assess for pain or other abnormalities and uterine size. At 16 weeks of gestation, the uterine fundus is palpable about midway between the symphysis pubis and umbilicus, while at 20 weeks it is palpable at about the level of the umbilicus. After the abdominal examination, the patient is placed in the lithotomy position. The external genitalia are examined and then a speculum is inserted into the vagina. As discussed above, physical examination may reveal a nonpregnancy-related source of bleeding, such as cervical ectropion, an abnormal growth, a laceration, or sanguinous-purulent discharge.",
"   </p>",
"   <p>",
"    Direct visualization of a dilated cervix or fetal membranes may be sufficient to diagnose impending miscarriage if contractions are present, or cervical insufficiency in the absence of contractions.",
"   </p>",
"   <p>",
"    Transvaginal ultrasonography is also the cornerstone in the evaluation of bleeding in the second trimester. The primary goals are to determine whether the placenta is covering the cervical os (placenta previa), whether there is evidence of decidual hemorrhage causing placental separation (ie, abruptio placenta), and whether the cervix shows signs suggestive of cervical insufficiency (short length, dilated internal os, funneling of the fetal membranes). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/33/21017?source=see_link\">",
"     \"Transvaginal ultrasound assessment of the cervix and prediction of spontaneous preterm birth\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4457?source=see_link\">",
"     \"Cervical insufficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Differential diagnosis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Miscarriage&nbsp;(see",
"      <a class=\"local\" href=\"#H10\">",
"       'Threatened miscarriage'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Inevitable miscarriage'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Complete and incomplete miscarriage'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Missed abortion'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Cervical, vaginal, or uterine pathology&nbsp;(see",
"      <a class=\"local\" href=\"#H15\">",
"       'Vaginitis, trauma, cancer, warts, polyps, fibroids'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Cervical insufficiency &mdash; The diagnosis of cervical insufficiency is clinical; the classic presentation is cervical dilatation and effacement in the second trimester with fetal membranes visible at or beyond the external os in the absence of contractions. It may be asymptomatic or associated with one or more of the following: vaginal fullness or pressure; vaginal spotting or bleeding; an increased volume of watery, mucousy, or brown vaginal discharge; and vague discomfort in the lower abdomen or back. Sonographic findings of a short cervix, dilated internal cervical os,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      funneling support the diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4457?source=see_link\">",
"       \"Cervical insufficiency\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Abruption &mdash; Bleeding and cramping are the signs and symptoms of placental separation due to hemorrhage into the decidual basalis. The diagnosis is one of exclusion since placental separation usually cannot be visualized on ultrasound examination. The presence of a subchorionic hematoma or placenta that covers the internal cervical os supports the diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/23/19834?source=see_link&amp;anchor=H33#H33\">",
"       \"Spontaneous abortion: Risk factors, etiology, clinical manifestations, and diagnostic evaluation\", section on 'Ultrasonography'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Ectopic pregnancy &mdash; Ectopic pregnancy is rare at this gestational age. When an ectopic pregnancy is diagnosed after the first trimester, the location is likely to be nontubal (abdominal, cervical, cesarean scar, or cornual) or heterotopic (ie, coexistent intrauterine and extrauterine pregnancies). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/4/16457?source=see_link\">",
"       \"Abdominal pregnancy, cesarean scar pregnancy, and heterotopic pregnancy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/51/11062?source=see_link\">",
"       \"Cervical pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Bleeding after 20 weeks of gestation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term antepartum hemorrhage typically refers to uterine bleeding after 20 weeks of gestation that is unrelated to labor and delivery. Antepartum hemorrhage complicates 4 to 5 percent of pregnancies. The major causes are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Placenta previa (20 percent)",
"     </li>",
"     <li>",
"      Abruptio placenta (30 percent)",
"     </li>",
"     <li>",
"      Uterine rupture (rare)",
"     </li>",
"     <li>",
"      Vasa previa (rare)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the remaining cases, the exact etiology of the antepartum bleeding cannot be determined and is frequently attributed to marginal separation of the placenta.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to bleeding in the first half of pregnancy, digital examination of the cervix",
"    <strong>",
"     SHOULD BE AVOIDED",
"    </strong>",
"    in women presenting with bleeding in the second half of pregnancy until placenta previa has been excluded. Digital examination of a placenta previa can cause immediate, severe hemorrhage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Differential diagnosis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Placenta previa &mdash; Placenta previa should be suspected in any woman who presents with vaginal bleeding in the second half of pregnancy. Classically, the absence of abdominal pain and uterine contractions was considered the clinical feature that distinguished between placenta previa and abruptio placenta, which is the other major cause of vaginal bleeding at this time. However, some women with placenta previa have uterine contractions in addition to bleeding; thus, the diagnosis of placenta previa must be determined by sonographic examination. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/13/35032?source=see_link\">",
"       \"Clinical features, diagnosis, and course of placenta previa\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Abruptio placenta &mdash; Abruptio placenta refers to premature separation of a normally implanted placenta prior to delivery of the infant. The most common risk factors include prior placental abruption, trauma, smoking, cocaine use, hypertension, and preterm premature rupture of the membranes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Clinically, placental abruption typically presents with vaginal bleeding (80 percent), uterine tenderness (70 percent), and uterine contractions (35 percent), with or without nonreassuring fetal testing. Uterine tenderness is caused by extravasation of blood into the myometrium (called a Couvelaire uterus when the blood penetrates all the way through the myometrium to the peritoneal cavity). The amount of vaginal bleeding may not be a reliable indicator of the severity of the hemorrhage since bleeding may be concealed (retained in the uterine cavity). Ultrasound may show placental separation, but this is uncommon (only 2 percent of abruptions can be visualized on ultrasound); the major purpose of ultrasound examination is to exclude placenta previa. Abruption ranges from mild to severe (life threatening) and may be acute or chronic. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29417?source=see_link\">",
"     \"Placental abruption: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The possibility of abruption should always be considered in women who are being evaluated for trauma (eg, motor vehicle crash, fall, domestic violence). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/2/22569?source=see_link&amp;anchor=H20#H20\">",
"     \"Trauma in pregnancy\", section on 'Abruptio placentae'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Uterine rupture and vasa previa &mdash; Uterine rupture and vasa previa are rare causes of vaginal bleeding, and occur more often intrapartum than antepartum. Both may lead to fetal death. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/18/20775?source=see_link\">",
"       \"Velamentous umbilical cord insertion and vasa previa\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/10/5290?source=see_link\">",
"       \"Choosing the route of delivery after cesarean birth\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cervical, vaginal, or uterine pathology&nbsp;(see",
"      <a class=\"local\" href=\"#H15\">",
"       'Vaginitis, trauma, cancer, warts, polyps, fibroids'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with first trimester bleeding, episodes of second and third trimester bleeding are also associated with adverse pregnancy outcome, primarily preterm birth [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15465/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/3/35898?source=see_link&amp;anchor=H9#H9\">",
"     \"Risk factors for preterm labor and delivery\", section on 'Vaginal bleeding'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risk of adverse outcome appears to depend on the degree of bleeding (worse outcome with heavier bleeding) and the cause (worse outcome with bleeding from nonprevia source) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15465/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of pregnant women with vaginal bleeding depends on the numerous factors, including the gestational age, the cause of bleeding, the severity of bleeding, and fetal status. Management is discussed in the individual topic reviews on the specific causes of vaginal bleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/17/36113?source=see_link\">",
"       \"Patient information: Threatened miscarriage (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The clinician typically makes a provisional clinical diagnosis of the cause of vaginal bleeding based upon the patient's gestational age and the character of her bleeding (light or heavy, associated with pain or painless, intermittent or constant). Laboratory and imaging tests are then used to confirm or revise the initial diagnosis. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The four major causes of bleeding in early pregnancy are: ectopic pregnancy; threatened or impending miscarriage; physiologic (ie, related to implantation of the pregnancy), and cervical, vaginal, or uterine pathology. Transvaginal ultrasonography is the cornerstone of the evaluation of bleeding in early pregnancy. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'First trimester bleeding'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An important goal in the evaluation of women with bleeding in early pregnancy is to exclude the possibility of ectopic pregnancy, since ruptured ectopic pregnancies can result in severe hemorrhage and death. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Ectopic pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The major causes of bleeding in the second and third trimesters are: bloody show associated with cervical insufficiency or labor; placenta previa; abruptio placenta; and rarely uterine rupture or vasa previa. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Second and third trimester bleeding'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Digital examination of the cervix",
"      <strong>",
"       should be avoided",
"      </strong>",
"      in women presenting with bleeding in the second half of pregnancy until placenta previa has been excluded because digital examination of a placenta previa can cause immediate, severe hemorrhage. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Bleeding after 20 weeks of gestation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with uterine bleeding who are Rh(D)-negative, we recommend anti-D immune globulin to protect against Rh(D) alloimmunization (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40648?source=see_link\">",
"       \"Prevention of Rh(D) alloimmunization\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15465/abstract/1\">",
"      Macones GA, Hankins GD, Spong CY, et al. The 2008 National Institute of Child Health and Human Development workshop report on electronic fetal monitoring: update on definitions, interpretation, and research guidelines. Obstet Gynecol 2008; 112:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15465/abstract/2\">",
"      Jindal P, Regan L, Fourkala EO, et al. Placental pathology of recurrent spontaneous abortion: the role of histopathological examination of products of conception in routine clinical practice: a mini review. Hum Reprod 2007; 22:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15465/abstract/3\">",
"      Isoardi K. Review article: the use of pelvic examination within the emergency department in the assessment of early pregnancy bleeding. Emerg Med Australas 2009; 21:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15465/abstract/4\">",
"      Tongsong T, Srisomboon J, Wanapirak C, et al. Pregnancy outcome of threatened abortion with demonstrable fetal cardiac activity: a cohort study. J Obstet Gynaecol (Tokyo 1995) 1995; 21:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15465/abstract/5\">",
"      Tannirandorn Y, Sangsawang S, Manotaya S, et al. Fetal loss in threatened abortion after embryonic/fetal heart activity. Int J Gynaecol Obstet 2003; 81:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15465/abstract/6\">",
"      De Sutter P, Bontinck J, Schutysers V, et al. First-trimester bleeding and pregnancy outcome in singletons after assisted reproduction. Hum Reprod 2006; 21:1907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15465/abstract/7\">",
"      SPEERT H, GUTTMACHER AF. Frequency and significance of bleeding in early pregnancy. J Am Med Assoc 1954; 155:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15465/abstract/8\">",
"      Harville EW, Wilcox AJ, Baird DD, Weinberg CR. Vaginal bleeding in very early pregnancy. Hum Reprod 2003; 18:1944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15465/abstract/9\">",
"      Williams MA, Mittendorf R, Lieberman E, Monson RR. Adverse infant outcomes associated with first-trimester vaginal bleeding. Obstet Gynecol 1991; 78:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15465/abstract/10\">",
"      Berkowitz GS, Harlap S, Beck GJ, et al. Early gestational bleeding and pregnancy outcome: a multivariable analysis. Int J Epidemiol 1983; 12:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15465/abstract/11\">",
"      Ananth CV, Savitz DA. Vaginal bleeding and adverse reproductive outcomes: a meta-analysis. Paediatr Perinat Epidemiol 1994; 8:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15465/abstract/12\">",
"      Weiss JL, Malone FD, Vidaver J, et al. Threatened abortion: A risk factor for poor pregnancy outcome, a population-based screening study. Am J Obstet Gynecol 2004; 190:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15465/abstract/13\">",
"      Yang J, Hartmann KE, Savitz DA, et al. Vaginal bleeding during pregnancy and preterm birth. Am J Epidemiol 2004; 160:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15465/abstract/14\">",
"      Chung TK, Sahota DS, Lau TK, et al. Threatened abortion: prediction of viability based on signs and symptoms. Aust N Z J Obstet Gynaecol 1999; 39:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15465/abstract/15\">",
"      Gracia CR, Sammel MD, Chittams J, et al. Risk factors for spontaneous abortion in early symptomatic first-trimester pregnancies. Obstet Gynecol 2005; 106:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15465/abstract/16\">",
"      Harger JH, Hsing AW, Tuomala RE, et al. Risk factors for preterm premature rupture of fetal membranes: a multicenter case-control study. Am J Obstet Gynecol 1990; 163:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15465/abstract/17\">",
"      Hasan R, Baird DD, Herring AH, et al. Association between first-trimester vaginal bleeding and miscarriage. Obstet Gynecol 2009; 114:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15465/abstract/18\">",
"      Lykke JA, Dideriksen KL, Lidegaard O, Langhoff-Roos J. First-trimester vaginal bleeding and complications later in pregnancy. Obstet Gynecol 2010; 115:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15465/abstract/19\">",
"      Velez Edwards DR, Baird DD, Hasan R, et al. First-trimester bleeding characteristics associate with increased risk of preterm birth: data from a prospective pregnancy cohort. Hum Reprod 2012; 27:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15465/abstract/20\">",
"      McPherson JA, Odibo AO, Shanks AL, et al. Adverse outcomes in twin pregnancies complicated by early vaginal bleeding. Am J Obstet Gynecol 2013; 208:56.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15465/abstract/21\">",
"      Everett C. Incidence and outcome of bleeding before the 20th week of pregnancy: prospective study from general practice. BMJ 1997; 315:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15465/abstract/22\">",
"      Signore CC, Sood AK, Richards DS. Second-trimester vaginal bleeding: correlation of ultrasonographic findings with perinatal outcome. Am J Obstet Gynecol 1998; 178:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15465/abstract/23\">",
"      Parant O, Clouet-Delannoy M, Connan L, et al. [Metrorrhagia during the second trimester of pregnancy: obstetrical and perinatal outcome. A retrospective study including 85 cases]. J Gynecol Obstet Biol Reprod (Paris) 2000; 29:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15465/abstract/24\">",
"      McCormack RA, Doherty DA, Magann EF, et al. Antepartum bleeding of unknown origin in the second half of pregnancy and pregnancy outcomes. BJOG 2008; 115:1451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15465/abstract/25\">",
"      Towers CV, Burkhart AE. Pregnancy outcome after a primary antenatal hemorrhage between 16 and 24 weeks' gestation. Am J Obstet Gynecol 2008; 198:684.e1.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6799 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-2332FC6495-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_6_15465=[""].join("\n");
var outline_f15_6_15465=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      FIRST TRIMESTER BLEEDING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - History",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Physical examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Laboratory tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Differential diagnosis and management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Ectopic pregnancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Threatened miscarriage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Inevitable miscarriage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Complete and incomplete miscarriage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Missed abortion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Vanishing twin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Vaginitis, trauma, cancer, warts, polyps, fibroids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Ectropion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Physiologic or implantation bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SECOND AND THIRD TRIMESTER BLEEDING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Prior to 20 weeks of gestation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Bleeding after 20 weeks of gestation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/6799\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6799|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/45/2783\" title=\"picture 1A\">",
"      Chorionic villi1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/56/31617\" title=\"picture 1B\">",
"      Chorionic villi2",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/4/16457?source=related_link\">",
"      Abdominal pregnancy, cesarean scar pregnancy, and heterotopic pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/4/64?source=related_link\">",
"      Acute cervicitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/44/36554?source=related_link\">",
"      Approach to abdominal pain and the acute abdomen in pregnant and postpartum women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/49/36633?source=related_link\">",
"      Approach to women with symptoms of vaginitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4457?source=related_link\">",
"      Cervical insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/51/11062?source=related_link\">",
"      Cervical pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/10/5290?source=related_link\">",
"      Choosing the route of delivery after cesarean birth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/13/35032?source=related_link\">",
"      Clinical features, diagnosis, and course of placenta previa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1178?source=related_link\">",
"      Clinical manifestations, diagnosis, and management of ectopic pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/38/23144?source=related_link\">",
"      Condylomata acuminata (anogenital warts)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23048?source=related_link\">",
"      Congenital cervical anomalies and benign cervical lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/17/6426?source=related_link\">",
"      Epidemiology, clinical manifestations, diagnosis, and natural history of uterine leiomyomas (fibroids)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/2/44071?source=related_link\">",
"      Evaluation and management of lower genital tract trauma in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/60/21444?source=related_link\">",
"      Expectant management of ectopic pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/11/24761?source=related_link\">",
"      Gestational trophoblastic disease: Epidemiology, clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/15/21752?source=related_link\">",
"      Incidence, risk factors, and pathology of ectopic pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28537?source=related_link\">",
"      Invasive cervical cancer: Epidemiology, risk factors, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/49/27417?source=related_link\">",
"      Methotrexate treatment of tubal and interstitial ectopic pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/17/36113?source=related_link\">",
"      Patient information: Threatened miscarriage (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29417?source=related_link\">",
"      Placental abruption: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/6/2154?source=related_link\">",
"      Pregnancy outcome after assisted reproductive technology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40648?source=related_link\">",
"      Prevention of Rh(D) alloimmunization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/3/35898?source=related_link\">",
"      Risk factors for preterm labor and delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/49/2841?source=related_link\">",
"      Spontaneous abortion: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/23/19834?source=related_link\">",
"      Spontaneous abortion: Risk factors, etiology, clinical manifestations, and diagnostic evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/53/5976?source=related_link\">",
"      Surgical treatment of ectopic pregnancy and prognosis for subsequent fertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/33/21017?source=related_link\">",
"      Transvaginal ultrasound assessment of the cervix and prediction of spontaneous preterm birth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/2/22569?source=related_link\">",
"      Trauma in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/46/40682?source=related_link\">",
"      Twin pregnancy: Prenatal issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31208?source=related_link\">",
"      Vaginal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/18/20775?source=related_link\">",
"      Velamentous umbilical cord insertion and vasa previa",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_6_15466="Staging and prognosis of chronic lymphocytic leukemia";
var content_f15_6_15466=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Staging and prognosis of chronic lymphocytic leukemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/6/15466/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/6/15466/contributors\">",
"     Kanti R Rai, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/6/15466/contributors\">",
"     Michael J Keating, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/6/15466/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/6/15466/contributors\">",
"     Richard A Larson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/6/15466/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/6/15466/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/6/15466/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 7, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic lymphocytic leukemia (CLL) is one of the chronic lymphoproliferative disorders (lymphoid neoplasms). According to the WHO classification, B cell chronic lymphocytic leukemia is considered to be identical (ie, one disease at different stages) to the mature (peripheral) B cell neoplasm small lymphocytic lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15466/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. It is characterized by a progressive accumulation of functionally incompetent lymphocytes, which are monoclonal in origin.",
"   </p>",
"   <p>",
"    The staging and prognosis of CLL will be reviewed here. The pathophysiology, clinical manifestations, diagnosis, and treatment of B cell CLL, including hematopoietic cell transplantation, are discussed separately on the appropriate topic reviews. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/38/35431?source=see_link\">",
"     \"Pathologic features, diagnosis, and differential diagnosis of chronic lymphocytic leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/28/18887?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of small lymphocytic lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/42/29352?source=see_link\">",
"     \"Overview of the treatment of chronic lymphocytic leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35017?source=see_link\">",
"     \"Overview of the complications of chronic lymphocytic leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There had been a general belief that CLL is an indolent disease associated with a prolonged (ie, 10 to 20 years) clinical course, and that the eventual cause of death may be unrelated to CLL. However, this observation is true for less than 30 percent of all CLL cases. Some patients die rapidly, within two to three years from diagnosis, from complications or causes directly related to CLL. Other patients live for 5 to 10 years with an initial course that is relatively benign followed by a terminal phase lasting one to two years. During this terminal phase there is considerable morbidity, both from the disease itself and from complications of therapy. The biologic reasons behind this clinical variability are under intense study, and are discussed below. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Clinical staging and prognosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    During the initial asymptomatic phase, patients are able to maintain their usual lifestyles, but during the terminal phase the performance status is poor, with recurring need for hospitalization. The most frequent causes of death are severe systemic infection (especially pneumonia and septicemia), bleeding, and inanition with cachexia. Spontaneous clinical regression has been reported, but is rare [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15466/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL STAGING AND PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the natural history of CLL is extremely variable, with survival times from initial diagnosis that range from 2 to 20 years, and a median survival of approximately 10 years. Until the mid 1970s, there were no reliable clinically applicable criteria that would allow the prospective separation of patients with a poor outlook for survival from those with an excellent prognosis. This difficulty forced physicians to make decisions concerning the need for, and timing of, therapeutic intervention in their patients with CLL, almost exclusively on an empiric basis.",
"   </p>",
"   <p>",
"    Reports published between 1966 and 1973 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15466/abstract/5-7\">",
"     5-7",
"    </a>",
"    ] constituted the basis on which Rai and colleagues developed a system of staging of CLL that could prospectively distinguish patients according to their overall outlook for survival [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15466/abstract/8\">",
"     8",
"    </a>",
"    ]. This method of staging was recognized as a simple, yet accurate predictor of survival and received wide acceptance by clinicians.",
"   </p>",
"   <p>",
"    With the advent of reliable criteria of stratification according to survival outlook, the Cancer and Leukemia Group B was able to initiate clinical trials in patients at different stages of this disease to test different therapeutic strategies [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15466/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    During the ensuing years, several additional systems of clinical staging have been proposed by investigators around the world, each having certain merits. A few of these staging systems are summarized below but only two, the Rai system [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15466/abstract/8\">",
"     8",
"    </a>",
"    ] and the Binet system [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15466/abstract/11\">",
"     11",
"    </a>",
"    ], are in wide use in clinical practice as well as in research. The International Workshop Group on CLL (IWCLL) recommends that, in practice, an integrated system using both methods should be used [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15466/abstract/12\">",
"     12",
"    </a>",
"    ]. According to this recommendation, each Binet stage is to be further identified by the appropriate Rai stage (eg, A0, AI, AII, BI, BII, CIII, CIV). However, this integrated system has not been widely accepted and most clinicians today use either the Rai or Binet method for patient management and therapeutic investigation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Rai staging system",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Rai system is based upon the concept that in CLL there is a gradual and progressive increase in the body burden of leukemic lymphocytes, starting in the blood and bone marrow (lymphocytosis), progressively involving lymph nodes (lymphadenopathy), spleen and liver (organomegaly), with eventual compromise of bone marrow function (anemia and thrombocytopenia) (",
"    <a class=\"graphic graphic_table graphicRef56284 \" href=\"UTD.htm?10/23/10619\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15466/abstract/13\">",
"     13",
"    </a>",
"    ]. At the time of initial diagnosis, the breakdown into the various stages is approximately:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Stage 0 (lymphocytosis) &mdash; 25 percent",
"     </li>",
"     <li>",
"      Stages I to II (lymphadenopathy, organomegaly) &mdash; 50 percent",
"     </li>",
"     <li>",
"      Stages III to IV (anemia, thrombocytopenia) &mdash; 25 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The median survival from the time of diagnosis in the series of patients was [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15466/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Stage 0 &mdash; 150 months",
"     </li>",
"     <li>",
"      Stage I &mdash; 101 months",
"     </li>",
"     <li>",
"      Stage II &mdash; 71 months",
"     </li>",
"     <li>",
"      Stages III and IV &mdash; 19 months",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although Rai and colleagues noted that there were only three distinct actuarial survival patterns (stage O, stages I and II combined, and stages III and IV combined), they recommended that the five-stage system be maintained to investigate prospectively whether biological and clinical differences would emerge between stages I and II and between stages III and IV. It became apparent in the 1980s, however, that it was impractical to stratify patients in five categories for prospective randomized trials. As a result, the staging system was modified to consist of three groups [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15466/abstract/14\">",
"     14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Low risk &mdash; Rai stage O",
"     </li>",
"     <li>",
"      Intermediate risk &mdash; Rai stages I and II combined",
"     </li>",
"     <li>",
"      High risk &mdash; Rai stages III and IV combined",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    With the passage of time, patients tend to progress from an early stage to an intermediate stage and eventually into an advanced stage [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15466/abstract/8\">",
"     8",
"    </a>",
"    ]. However, if complete or partial remission is achieved with successful therapy, and a patient's stage shifts from a higher risk to a lower risk category, the outlook for survival improves accordingly [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15466/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Binet staging system",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Binet staging system takes into consideration five potential sites of involvement: cervical, axillary, and inguinal lymph nodes (whether unilateral or bilateral, each area is counted as one), spleen, and liver. Patients are classified according to the number of involved sites plus the presence of anemia (hemoglobin &lt;10",
"    <span class=\"nowrap\">",
"     g/dL)",
"    </span>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    thrombocytopenia (platelets",
"    <span class=\"nowrap\">",
"     &lt;100,000/microL)",
"    </span>",
"    (",
"    <a class=\"graphic graphic_table graphicRef80421 \" href=\"UTD.htm?0/50/811\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Stage A &mdash; Fewer than three involved lymphoid sites",
"     </li>",
"     <li>",
"      Stage B &mdash; Three or more involved lymphoid sites",
"     </li>",
"     <li>",
"      Stage C &mdash; Presence of anemia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      thrombocytopenia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This system is of great value in stratifying patients with survival curves corresponding to the Rai low risk, intermediate risk, and high risk groups, respectively. Median survival for the prognostic groups studied by Binet was [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15466/abstract/16\">",
"     16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Stage A &mdash; comparable to age-matched controls",
"     </li>",
"     <li>",
"      Stage B &mdash; 84 months",
"     </li>",
"     <li>",
"      Stage C &mdash; 24 months",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Computed tomography (CT) of the chest, abdomen, and pelvis is not routinely performed as part of the staging of patients with CLL outside of a clinical trial, but may be indicated based upon the patient's symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15466/abstract/17\">",
"     17",
"    </a>",
"    ]. CT scans may reveal enlargement of retroperitoneal or mediastinal nodes that are currently not included among the five sites of palpably enlarged lymphoid areas. It is not clear whether such findings should be incorporated into the Binet staging system.",
"   </p>",
"   <p>",
"    Patients with cytopenias due to autoimmune processes appear to have a better prognosis than patients with cytopenias due to bone marrow failure [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15466/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. This issue was addressed by a single institution retrospective study of 960 patients with CLL that identified an autoimmune cytopenia in 70 patients (7 percent) at some point during the disease process [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15466/abstract/19\">",
"     19",
"    </a>",
"    ]. Patients who were classified as stage C due to autoimmune cytopenias had a significantly better median survival than patients with cytopenias due to bone marrow infiltration (7.4 versus 3.7 years) and a worse median survival than those with stage A disease (10.2 years). Many patients with autoimmune cytopenias were able to normalize their blood counts after therapy directed at the autoimmune process and thereby postpone the initiation of chemotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     OTHER PROGNOSTIC FACTORS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described in the previous section, the Rai and Binet staging systems were designed to provide prognostic information for patient care. Both of these systems are in wide use in clinical practice.",
"   </p>",
"   <p>",
"    However, some patients classified as having early stage disease rapidly progress. For this reason, other prognostic factors have been investigated. Age, sex, and performance status have been correlated with prognosis but the significance and magnitude of this effect has varied among studies [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15466/abstract/20\">",
"     20",
"    </a>",
"    ]. In separate studies, other factors have been correlated with shorter survival (",
"    <a class=\"graphic graphic_table graphicRef74103 \" href=\"UTD.htm?29/18/29995\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The following section provides an introduction to many of these factors. Only lymphocyte doubling time and cytogenetic abnormalities are currently used clinically to provide prognostic information or guide therapy. Treatment based on newer prognostic markers (eg, CD38, ZAP-70, or VH gene mutation status) alone in asymptomatic patients with early stage disease cannot be recommended outside of a clinical trial [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15466/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several prognostic factors have been tested and found to be of limited, if any, usefulness in predicting the course of nonadvanced stages of CLL [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15466/abstract/4,22\">",
"     4,22",
"    </a>",
"    ]. These prognostic factors include: extent of blood lymphocytosis, morphologic features of blood lymphocytes, ie, the relative proportion of prolymphocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15466/abstract/23,24\">",
"     23,24",
"    </a>",
"    ], presence of normal or abnormal chromosomal karyotype, phenotypic profile of B-lymphocytes, age, sex [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15466/abstract/25,26\">",
"     25,26",
"    </a>",
"    ], and levels of serum immunoglobulins [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15466/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Lymphocyte doubling time",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lymphocyte doubling time (LDT) is the number of months it takes the absolute lymphocyte count to double. This can provide an estimation of the tempo of the disease; however, this factor is somewhat limited in usefulness because it takes time to measure. An actual or projected LDT in untreated patients &lt;12 months predicts a progressive course and a longer LDT predicts an indolent course [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15466/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with early stage disease, the presence of a short doubling time may favor more aggressive therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/46/30442?source=see_link\">",
"     \"Treatment of relapsed or refractory chronic lymphocytic leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Genetic abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific cytogenetic abnormalities identified by karyotype analysis and abnormalities in certain genes identified by molecular genetic testing confer prognostic significance in patients with CLL. Our understanding regarding the prognostic value of specific cytogenetic and molecular findings in CLL is rapidly changing. While initial attempts have been made to incorporate this information into clinical practice, these will undoubtedly change in the future as the impact of combinations of molecular findings is analyzed further. Specific details regarding these individual cytogenetic abnormalities in CLL are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/23/42361?source=see_link\">",
"     \"Pathophysiology and genetic features of chronic lymphocytic leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A prognostic scoring system that integrates cytogenetic and molecular features in CLL was developed based upon an initial analysis of samples from 637 patients with newly diagnosed and previously untreated CLL [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15466/abstract/31\">",
"     31",
"    </a>",
"    ]. Initial treatment included",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    -based regimens (46 percent),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    -based regimens (24 percent), and alkylator-based regimens (30 percent). This system was further validated in an independent cohort of 370 patients with newly diagnosed and previously untreated CLL. The prognostic scoring system divided cases into four prognostic risk groups with significantly different rates of overall survival (OS) at five and 10 years:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High risk (27 percent) &mdash; TP53",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <em>",
"       BIRC3",
"      </em>",
"      abnormalities &mdash; Five-year OS 51 percent; 10-year OS 29 percent",
"     </li>",
"     <li>",
"      Intermediate risk (39 percent) &mdash;",
"      <em>",
"       NOTCH1",
"      </em>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <em>",
"       SF3B1",
"      </em>",
"      mutations",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      del11q22-q23 &mdash; Five-year OS 66 percent; 10-year OS 37 percent",
"     </li>",
"     <li>",
"      Low risk (17 percent) &mdash; harboring +12 or normal genetics &mdash; Five-year OS 78 percent; 10-year OS 57 percent",
"     </li>",
"     <li>",
"      Very low risk (17 percent) &mdash; del13q14 only &mdash; Five-year OS 87 percent; 10-year OS 69 percent; OS in this group did not significantly differ from a matched general population.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, sequential tumor samples from 257 individuals in the training cohort demonstrated that this scoring system retained prognostic value at one, two, and four years after diagnosis. This study provides further insight into the prognosis of CLL according to tumor molecular genetics. Application of this scoring system in prospective studies with uniform treatment will provide further clarity into the prognostic value of this system.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Bone marrow histologic pattern",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pattern of lymphocyte infiltration in the bone marrow biopsy specimen is an independent prognostic marker. A diffuse pattern predicts a progressive course and a non-diffuse (interstitial and nodular) pattern predicts a more indolent course [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15466/abstract/32-35\">",
"     32-35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Beta-2 microglobulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beta-2 microglobulin levels correlate with disease stage and tumor burden in patients with CLL, with increasing levels associated with a poorer prognosis (",
"    <a class=\"graphic graphic_figure graphicRef66198 \" href=\"UTD.htm?0/9/156\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15466/abstract/36\">",
"     36",
"    </a>",
"    ]. B2M may be regulated, at least in part, by exogenous cytokines [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15466/abstract/37\">",
"     37",
"    </a>",
"    ]. The source of these elevated cytokines in CLL is unclear, although IL-6, which inhibits apoptosis in CLL cells, may be released from vascular endothelium [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15466/abstract/38\">",
"     38",
"    </a>",
"    ]. B2M levels also rise with worsening renal dysfunction leading some investigators to suggest a measure of B2M adjusted for the glomerular filtration rate (GFR-adjusted B2M) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15466/abstract/39\">",
"     39",
"    </a>",
"    ]. This GFR-adjusted B2M requires validation in prospective confirmatory studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     IgVH mutation status",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutated immunoglobulin variable heavy chain (IgVH) genes are defined in most studies as having a greater than 2 percent difference in nucleotide sequence compared with germline DNA [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15466/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. Approximately half of CLL clones will demonstrate unmutated immunoglobulin variable heavy chains, a finding associated with shorter survival overall and a higher risk of relapse following treatment, including hematopoietic cell transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15466/abstract/40-47\">",
"     40-47",
"    </a>",
"    ]. This is a technically difficult study to perform and is not widely available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     CD38",
"    </span>",
"    &nbsp;&mdash;&nbsp;Detection of CD38 positivity by flow-cytometry initially appeared to correlate with the presence of unmutated immunoglobulin variable heavy chains in CLL [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15466/abstract/40\">",
"     40",
"    </a>",
"    ]. The presence of CD38 appears to be independently associated with an adverse prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15466/abstract/48-54\">",
"     48-54",
"    </a>",
"    ]. This may be due to specific changes in the expression of certain genes, particularly HEM1 (associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    resistance) and the ataxia telangiectasia mutated gene (which interferes with apoptosis) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15466/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     ZAP 70",
"    </span>",
"    &nbsp;&mdash;&nbsp;Zeta chain associated protein 70 (ZAP 70), a tyrosine kinase normally expressed by NK and T cells, is required for normal T cell receptor signaling. ZAP 70 is not normally expressed in B lymphocytes, but has been found in a subset of patients with CLL and appears to correlate with survival. The best cutoff value for determining ZAP 70 positivity is unclear and levels appear to change over time [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15466/abstract/55\">",
"     55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/2/42022?source=see_link\">",
"     \"ZAP-70 deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite the uncertainty concerning normal threshold values, increased levels of ZAP-70 detected by flow cytometry denote a poor prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15466/abstract/56\">",
"     56",
"    </a>",
"    ]. In addition, abnormal expression of ZAP-70 in CLL B cells is strongly associated with the presence of an unmutated Ig heavy chain variable region gene (IgVH), another poor prognostic factor (as previously noted) (",
"    <a class=\"graphic graphic_figure graphicRef57605 \" href=\"UTD.htm?10/13/10463\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15466/abstract/56,57\">",
"     56,57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Other markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of other prognostic markers have been studied, but their actual place in today&rsquo;s clinical practice has not been established. These markers have been included for completeness of this discussion.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with CLL have a similar rate of vitamin D deficiency as that seen in the general population (approximately 30 to 40 percent). A prospective cohort analysis identified low vitamin D levels (&lt;25",
"      <span class=\"nowrap\">",
"       ng/mL)",
"      </span>",
"      as a marker of poor prognosis in 390 patients with newly diagnosed CLL and confirmed this prognostic value in a second cohort of 153 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?15/6/15466/abstract/58\">",
"       58",
"      </a>",
"      ]. On multivariate analysis, vitamin D deficiency was associated with a shorter time to initiation of treatment (hazard ratio 1.47; 95% CI 1.11 to 1.96) and a trend towards shorter survival (hazard ratio 1.47; 95% CI 0.97 to 2.23). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/21/3417?source=see_link\">",
"       \"Treatment of vitamin D deficiency in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Increased plasma IL-8 levels (&gt;26.2",
"      <span class=\"nowrap\">",
"       pg/mL)",
"      </span>",
"      have been correlated with reduced survival (9 versus 63 months for those with IL-8 levels below this value; relative risk 7.4, 95% CI: 3.8-14.7) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/6/15466/abstract/59\">",
"       59",
"      </a>",
"      ]. IL-8 levels were predictive of survival independent of B2M levels as well as Rai stage.",
"     </li>",
"     <li>",
"      In one study, increased plasma levels of the B cell marker CD20 &ge;1875",
"      <span class=\"nowrap\">",
"       nM/L",
"      </span>",
"      correlated with reduced survival (relative risk 3.5) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/6/15466/abstract/60\">",
"       60",
"      </a>",
"      ]. The adverse prognostic value of this finding was independent of Rai stage or hemoglobin level. Whether dosing of the anti-CD20 antibody",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      should be adjusted according to plasma CD20 levels is not known at this time.",
"     </li>",
"     <li>",
"      A prospective study of 339 patients with CLL reported that the 49 percent of patients who had abnormality in free light chain assays (eg, monoclonal, polyclonal, or",
"      <span class=\"nowrap\">",
"       kappa/lambda",
"      </span>",
"      ratio abnormalities) had a shorter time to initial therapy than those with normal free light chain assays [",
"      <a class=\"abstract\" href=\"UTD.htm?15/6/15466/abstract/61\">",
"       61",
"      </a>",
"      ]. Patients with either monoclonal or polyclonal abnormalities had inferior overall survival when compared with those with normal or",
"      <span class=\"nowrap\">",
"       kappa/lambda",
"      </span>",
"      only abnormalities. These results have been confirmed in another cohort [",
"      <a class=\"abstract\" href=\"UTD.htm?15/6/15466/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study of 127 patients with CLL, high plasma levels of thrombopoietin (TPO) and B2M were associated with shorter survival [",
"      <a class=\"abstract\" href=\"UTD.htm?15/6/15466/abstract/63\">",
"       63",
"      </a>",
"      ]. On multivariate analysis the adverse effect of high levels of TPO on survival was independent of VH gene mutation status, B2M, and Rai stage.",
"     </li>",
"     <li>",
"      MicroRNAs (miRNAs) are small noncoding RNAs that modulate the expression of genes at the posttranscriptional level. The decreased expression of specific microRNAs (eg, miR-223 and miR-29c) has been associated with reduced overall survival in retrospective analyses [",
"      <a class=\"abstract\" href=\"UTD.htm?15/6/15466/abstract/64,65\">",
"       64,65",
"      </a>",
"      ]. Confirmation in prospective trials is required to validate their prognostic value. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/23/42361?source=see_link&amp;anchor=H15#H15\">",
"       \"Pathophysiology and genetic features of chronic lymphocytic leukemia\", section on 'MicroRNA'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Low and intermediate risk groups",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although virtually all patients in the high risk group (Rai stages III and IV or Binet stage C) have a relatively rapid clinical course and mortality within approximately four years, the course of disease is not uniform in the other risk groups. Patients in the low and intermediate risk groups (stage 0, and stages I and II, respectively) may have a benign clinical course in which the disease remains indolent for several years or decades. In others, the course may be progressive and associated with a short duration of survival.",
"   </p>",
"   <p>",
"    The need to prospectively predict the clinical course of CLL in these risk groups is therefore crucial. However, no currently available method of staging is of value for this purpose, although studies using positivity for CD38 and immunoglobulin heavy chain variable gene mutational status appear promising (see",
"    <a class=\"local\" href=\"#H21\">",
"     'Role of CD38, ZAP-70, and VH gene mutation status'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15466/abstract/20,66\">",
"     20,66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Indolent or smoldering disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the low-risk group, several investigators have discovered clinical criteria that may identify patients whose disease will remain indolent or smoldering, as distinct from those whose disease will progress to higher risk groups [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15466/abstract/67-71\">",
"     67-71",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one report of Spanish patients in Binet stage A, a lymphocyte count",
"      <span class=\"nowrap\">",
"       &lt;30,000/microL,",
"      </span>",
"      a blood lymphocyte doubling time &gt;12 months, hemoglobin &ge;13",
"      <span class=\"nowrap\">",
"       g/dL,",
"      </span>",
"      and bone marrow biopsy showing a non-diffuse (interstitial or nodular) pattern of lymphoid infiltration was associated with \"smoldering\" CLL, with survival statistics similar to those of an age and sex-matched Spanish population [",
"      <a class=\"abstract\" href=\"UTD.htm?15/6/15466/abstract/67,70\">",
"       67,70",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a series from France, Binet stage A patients with a hemoglobin concentration &gt;12",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      and blood lymphocytosis of",
"      <span class=\"nowrap\">",
"       &lt;30,000/microL",
"      </span>",
"      had a survival time equal to that of an age and sex matched French population [",
"      <a class=\"abstract\" href=\"UTD.htm?15/6/15466/abstract/72\">",
"       72",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An Italian study found that Binet stage A patients with low serum concentrations of vascular endothelial growth factor (VEGF) had a median progression-free survival (PFS) that was not reached at 40 months, significantly longer than patients with higher serum VEGF concentrations (median PFS 33 months) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/6/15466/abstract/73\">",
"       73",
"      </a>",
"      ]. CLL cells have been shown to produce VEGF, which may be important for expansion of lymphoid tissues, migration of CLL cells from blood to tissues,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      prolongation of the survival of these cells [",
"      <a class=\"abstract\" href=\"UTD.htm?15/6/15466/abstract/74\">",
"       74",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Other predictors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Criteria for defining \"smoldering\" CLL notwithstanding, the matter of accurately predicting the clinical course of CLL in all nonadvanced stages of the disease (ie, Rai stages 0, I, and II) still remains unresolved [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15466/abstract/75\">",
"     75",
"    </a>",
"    ]. It is likely, however, that both of the following criteria, when used together, will emerge as the needed solution of this problem:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The pattern of lymphocyte infiltration in the bone marrow biopsy specimen, with a diffuse pattern predicting a progressive course and a non-diffuse (interstitial and nodular) pattern predicting a more indolent course [",
"      <a class=\"abstract\" href=\"UTD.htm?15/6/15466/abstract/32-34\">",
"       32-34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The lymphocyte doubling time (LDT), with an actual or projected LDT in untreated patients &lt;12 months predicting a progressive course and a longer LDT predicting an indolent course [",
"      <a class=\"abstract\" href=\"UTD.htm?15/6/15466/abstract/29,30\">",
"       29,30",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A reliable prediction of the clinical course in low and intermediate risk cases can be made when both criteria point in the same direction (ie, diffuse bone marrow pattern combined with a short LDT or a non-diffuse bone marrow pattern coupled with a long LDT). Use of other predictors, such as CD38 positivity in early [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15466/abstract/76,77\">",
"     76,77",
"    </a>",
"    ] as well as late stage disease, is discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Defining good and poor prognostic groups",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been suggested, on the basis of clinical, cytogenetic, and molecular biological observations, that there may be two different \"types\" of CLL, which have some or all of the following characteristics (",
"    <a class=\"graphic graphic_table graphicRef74103 \" href=\"UTD.htm?29/18/29995\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15466/abstract/45,48-50,78-83\">",
"     45,48-50,78-83",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CLL developing from postgerminal center memory B cells, with mutated immunoglobulin heavy chain variable-region (VH) genes. In multiple studies, mutated VH gene status has, in general, correlated with the presence of more favorable chromosomal abnormalities, lowered expression of CD38 and ZAP-70, lower clinical stage, greater disease stability, and excellent survival.",
"     </li>",
"     <li>",
"      CLL developing from pregerminal center B cells, with unmutated VH genes. This finding correlated, in general, with the presence of less favorable chromosomal abnormalities, higher expression of CD38 and ZAP-70, higher clinical stage, greater tendency to disease progression, a poor response to treatment, and shorter survival.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A nomogram is available that incorporates many of these factors and predicts which asymptomatic patients are more likely to progress to symptomatic disease within two to four years (",
"    <a class=\"graphic graphic_figure graphicRef74145 \" href=\"UTD.htm?29/61/30686\">",
"     figure 3",
"    </a>",
"    ). Such patients may be candidates for clinical trials of early therapy. This nomogram is based on data from 930 previously untreated patients who presented to MD Anderson with asymptomatic CLL [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15466/abstract/84\">",
"     84",
"    </a>",
"    ]. A multivariable model evaluated time to first treatment and identified the following factors as significant: number of lymph node sites involved, size of largest lymph node in the neck, serum LDH, VH gene mutation status, and the presence of del(11q) or del(17p) on FISH. Using these six factors, the two-year treatment-free probability ranged from 10 percent to 95 percent and the median treatment-free survival ranged from 10 to 60 months. While these observations need to be confirmed by future prospective studies, the analyses were meticulously conducted and might prove to be very useful in identifying those patients who need aggressive front-line therapies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Role of CD38, ZAP-70, and VH gene mutation status",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relationships among lymphocyte developmental stage and morphology, CD38 and ZAP-70 positivity, genetic studies (eg, chromosomal changes, gene expression profiling, VH gene mutation status, microRNA signatures), and other cellular variables as important prognostic features are complex and the subject of considerable ongoing interest [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15466/abstract/85-98\">",
"     85-98",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 325 consecutive patients with CLL, the presence of unmutated variable region immunoglobulin heavy chain (VH) genes (ie, &ge;97 percent homology to the nearest germline gene) was associated with a hazard ratio of death of 5.3 (95 % CI 2.7-10), as compared with those with lesser degrees of VH homology (ie, mutated VH genes) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/6/15466/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a report including 205 patients with CLL and known VH mutation status, deletion of chromosome 11q23, absence of a deletion of chromosome 13q14, atypical lymphocyte morphology, and &gt;30 percent expression of CD38 were significantly associated with unmutated VH genes [",
"      <a class=\"abstract\" href=\"UTD.htm?15/6/15466/abstract/99\">",
"       99",
"      </a>",
"      ]. The median survivals of patients with mutated VH genes, unmutated VH genes, and loss or mutation of the p53 gene (regardless of VH gene status) were 310, 119, and 47 months, respectively. Patients with unmutated VH genes may have better outcomes with hematopoietic cell transplantation [",
"      <a class=\"abstract\" href=\"UTD.htm?15/6/15466/abstract/100,101\">",
"       100,101",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In other reports, positivity for the zeta chain-associated protein (ZAP)-70 has been highly correlated with the presence of unmutated VH genes and an inferior clinical outcome [",
"      <a class=\"abstract\" href=\"UTD.htm?15/6/15466/abstract/82,102-106\">",
"       82,102-106",
"      </a>",
"      ]. In our retrospective study, ZAP-70 positivity was a stronger predictor of the need for treatment in B cell CLL (hazard ratio 4.9; 95% CI 3.2-7.6) than was the presence of unmutated VH genes (HR 2.5; 95% CI 1.6-3.9) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/6/15466/abstract/107\">",
"       107",
"      </a>",
"      ]. The adverse prognostic significance of ZAP-70 may not be seen in patients treated with hematopoietic cell transplantation [",
"      <a class=\"abstract\" href=\"UTD.htm?15/6/15466/abstract/108\">",
"       108",
"      </a>",
"      ]. &nbsp;(See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/2/42022?source=see_link\">",
"       \"ZAP-70 deficiency\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      An Intergroup phase III trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      versus fludarabine plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      in 235 previously untreated CLL patients investigated the prognostic value of many of the above-noted disease markers [",
"      <a class=\"abstract\" href=\"UTD.htm?15/6/15466/abstract/109\">",
"       109",
"      </a>",
"      ]. Complete remission and overall response rates were not significantly different based on cytogenetics, VH mutation status, CD38 expression, or p53 mutational status.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, the occurrence of del(17p) or del(11q) was associated with reduced progression-free survival after an initial response, suggesting that patients with these high risk cytogenetic features should be considered for alternative non-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    -based therapy that act independently of p53 (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    , flavopiridol) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15466/abstract/110-113\">",
"     110-113",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/46/30442?source=see_link&amp;anchor=H7#H7\">",
"     \"Treatment of relapsed or refractory chronic lymphocytic leukemia\", section on 'Alemtuzumab'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/46/30442?source=see_link&amp;anchor=H16#H16\">",
"     \"Treatment of relapsed or refractory chronic lymphocytic leukemia\", section on 'Flavopiridol'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     HISTOLOGIC TRANSFORMATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a variable percent of patients with CLL, and usually as a terminal event, CLL transforms into another lymphoproliferative disorder. As noted in one of the largest epidemiologic surveys, patients with CLL, compared with the general population, appear to have a two- to fivefold increased risk of developing a second lymphoid malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15466/abstract/114\">",
"     114",
"    </a>",
"    ]. In approximately 60 percent of cases, the transformed cells are clonally related to the original B-CLL cells while, in the remaining 40 percent, they appear to be derived from a separate cell of origin [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15466/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following are the most commonly reported transformations:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Aggressive or highly aggressive lymphoma (Richter's transformation, RT) &mdash; 3 to 7 percent",
"     </li>",
"     <li>",
"      Prolymphocytic leukemia (PLL) &mdash; 2 percent",
"     </li>",
"     <li>",
"      Hodgkin lymphoma &mdash; 0.5 to 2 percent",
"     </li>",
"     <li>",
"      Multiple myeloma &mdash; 0.1 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is unclear whether treatment with either a purine nucleoside analogue or an anthracycline significantly increases the risk of a second lymphoid malignancy. A potentially increased incidence was initially suggested by an observational cohort study from the Mayo Clinic that followed 962 patients with CLL for a median of 3.3 years and reported that 26 patients (2.7 percent) developed a second lymphoid malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15466/abstract/115\">",
"     115",
"    </a>",
"    ]. In this study, prior treatment with a purine nucleoside analog or an anthracycline was associated with a higher likelihood of developing a second lymphoid malignancy. However, this association was not confirmed in the prospective CALGB 9011 study in which 521 patients with previously untreated CLL were randomly assigned to receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    , or both [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15466/abstract/116\">",
"     116",
"    </a>",
"    ]. After a minimum follow-up of 15 years, RT developed in 34 patients (7 percent) and PLL developed in 10 patients (2 percent). The incidence of RT and PLL was independent of initial therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Prolymphocytoid transformation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In approximately 10 percent of patients with CLL, the terminal event is a morphological transformation of blood lymphocytes from the typical small, mature-appearing cell to somewhat larger cells with distinct nucleoli and a less dense nuclear chromatin. This event, called prolymphocytoid transformation, occurs slowly over years and is associated with refractoriness to the usual chemotherapeutic agents [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15466/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. It is clinically and immunophenotypically distinct from de novo prolymphocytic leukemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/38/35431?source=see_link&amp;anchor=H11#H11\">",
"     \"Pathologic features, diagnosis, and differential diagnosis of chronic lymphocytic leukemia\", section on 'Prolymphocytic leukemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Richter's transformation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1 to 10 percent of patients with CLL, transformation to a highly aggressive non-Hodgkin lymphoma supervenes (Richter's syndrome or Richter's transformation [RT]) (",
"    <a class=\"graphic graphic_picture graphicRef53282 \" href=\"UTD.htm?11/54/12135\">",
"     picture 1",
"    </a>",
"    ). This transformation is heralded by sudden clinical deterioration, characterized by increasing lymphadenopathy, splenomegaly, worsening \"B\" symptoms (ie, fever, night sweats, weight loss), a rapidly progressive downhill clinical course, and a median survival of 5 to 8 months. This subject is discussed in depth separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3609?source=see_link\">",
"     \"Pathobiology and treatment of Richter's transformation in chronic lymphocytic leukemia/small lymphocytic lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Hodgkin lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a number of cases of histologic transformation of B-CLL to Hodgkin lymphoma (HL), single cell analysis indicated that the CLL cells and the isolated Reed-Sternberg (RS) cells belonged to the same clonal population [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15466/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. A relationship with Epstein-Barr virus infection and treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    has been suggested for these cases.",
"   </p>",
"   <p>",
"    In three other cases, RS-like cells were found in otherwise typical B-CLL in the absence of clinical transformation to HL [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15466/abstract/27\">",
"     27",
"    </a>",
"    ]. The RS-like cells were derived from the original B-CLL clone in one patient, but not in the other two, both of whose RS-like cells were infected with Epstein-Barr virus.",
"   </p>",
"   <p>",
"    In a retrospective review of 4121 patients with",
"    <span class=\"nowrap\">",
"     CLL/small",
"    </span>",
"    lymphocytic leukemia (SLL) seen at the M D Anderson Cancer center, 18 developed HL (0.4 percent) at a median time of 4.6 years after the diagnosis of",
"    <span class=\"nowrap\">",
"     CLL/SLL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/6/15466/abstract/28\">",
"     28",
"    </a>",
"    ]. The most common presenting symptoms of HL in this group included lymphadenopathy (79 percent), B-symptoms (67 percent), splenomegaly (43 percent), and hepatomegaly (29 percent). Fourteen patients received chemotherapy for HL, with an overall response rate of 44 percent (19 percent complete remission rate) and an extremely short median overall survival duration of 0.8 years, similar to that seen in patients with CLL and Richter's transformation (see above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Acute leukemic transformation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute leukemia is a rare terminal event in CLL and, when it does occur, is usually one of the myeloid variants (ie, acute myeloid leukemia, AML). Prior therapy with alkylating agents has not been clearly implicated in causation of terminal leukemia. AML developing in patients known to have CLL is treated with any of the acute leukemia therapy regimens, but with almost invariably poor outcome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/55/36730?source=see_link&amp;anchor=H6#H6\">",
"     \"Prognosis of acute myeloid leukemia\", section on 'Antecedent hematologic disorders'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?6/10/6309?source=see_link\">",
"       \"Patient information: Chronic lymphocytic leukemia (CLL) in adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34886?source=see_link\">",
"       \"Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic lymphocytic leukemia (CLL) is a chronic lymphoproliferative disorder (lymphoid neoplasm) characterized by a progressive accumulation of functionally incompetent lymphocytes, which are monoclonal in origin. The disorder is considered to be identical (ie, one disease at different stages) to the mature B cell neoplasm small lymphocytic lymphoma (SLL).",
"     </li>",
"     <li>",
"      CLL is an extremely heterogeneous disease. While there had been a general belief that CLL is an indolent disease associated with a prolonged (ie, 10 to 20 years) clinical course, this observation is true for less than 30 percent of all CLL cases. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Natural history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with CLL are grouped prognostically according to the Rai and Binet staging systems based on physical examination and complete blood counts (",
"      <a class=\"graphic graphic_table graphicRef56284 \" href=\"UTD.htm?10/23/10619\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef80421 \" href=\"UTD.htm?0/50/811\">",
"       table 2",
"      </a>",
"      ). Computed tomography of the chest, abdomen, and pelvis is not routinely performed outside of a clinical trial, but may be indicated based upon the patient's symptoms. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical staging and prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The variability in disease course suggests the need for prospective treatment protocols stratifying for combinations of the Rai or Binet clinical staging systems, along with incorporation of one or more biologic markers. Such studies should improve the clinician's ability to more reliably assess appropriate initial therapy and prognosis in all newly diagnosed patients with CLL. Treatment based on the newer prognostic markers alone in asymptomatic patients with early stage disease cannot be recommended outside of a clinical trial. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Other prognostic factors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/1\">",
"      Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17:3835.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Swerdlow SH, Campo E, Harris NL, et al. (Eds), IARC Press, Lyon 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/3\">",
"      Tsimberidou AM, Wen S, O'Brien S, et al. Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas M.D. Anderson Cancer Center. J Clin Oncol 2007; 25:4648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/4\">",
"      Thomas R, Ribeiro I, Shepherd P, et al. Spontaneous clinical regression in chronic lymphocytic leukaemia. Br J Haematol 2002; 116:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/5\">",
"      Boggs DR, Sofferman SA, Wintrobe MM, Cartwright GE. Factors influencing the duration of survival of patients with chronic lymphocytic leukemia. Am J Med 1966; 40:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/6\">",
"      Galton DA. The pathogenesis of chronic lymphocytic leukemia. Can Med Assoc J 1966; 94:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/7\">",
"      Hansen MM. Chronic lymphocytic leukaemia. Clinical studies based on 189 cases followed for a long time. Scand J Haematol Suppl 1973; 18:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/8\">",
"      Rai KR, Sawitsky A, Cronkite EP, et al. Clinical staging of chronic lymphocytic leukemia. Blood 1975; 46:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/9\">",
"      Sawitsky A, Rai KR, Glidewell O, Silver RT. Comparison of daily versus intermittent chlorambucil and prednisone therapy in the treatment of patients with chronic lymphocytic leukemia. Blood 1977; 50:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/10\">",
"      Shustik C, Mick R, Silver R, et al. Treatment of early chronic lymphocytic leukemia: intermittent chlorambucil versus observation. Hematol Oncol 1988; 6:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/11\">",
"      Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981; 48:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/12\">",
"      Chronic lymphocytic leukemia: recommendations for diagnosis, staging, and response criteria. International Workshop on Chronic Lymphocytic Leukemia. Ann Intern Med 1989; 110:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/13\">",
"      Epstein AL, Marder RJ, Winter JN, et al. Two new monoclonal antibodies, Lym-1 and Lym-2, reactive with human B-lymphocytes and derived tumors, with immunodiagnostic and immunotherapeutic potential. Cancer Res 1987; 47:830.",
"     </a>",
"    </li>",
"    <li>",
"     Rai KR. A critical analysis of staging in CLL. In: Chronic Lymphocytic Leukemia: Recent Progress and future Direction. 1987 UCLA Symposia on Molecular and Cellular Biology, New Series, Vol. 59. Gale RP, Rai KR (Eds). Alan R Liss, New York 1987. p.253.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/15\">",
"      Keating MJ, Scouros M, Murphy S, et al. Multiple agent chemotherapy (POACH) in previously treated and untreated patients with chronic lymphocytic leukemia. Leukemia 1988; 2:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/16\">",
"      Binet JL, Lepoprier M, Dighiero G, et al. A clinical staging system for chronic lymphocytic leukemia: prognostic significance. Cancer 1977; 40:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/17\">",
"      Blum KA, Young D, Broering S, et al. Computed tomography scans do not improve the predictive power of 1996 national cancer institute sponsored working group chronic lymphocytic leukemia response criteria. J Clin Oncol 2007; 25:5624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/18\">",
"      Zent CS, Ding W, Schwager SM, et al. The prognostic significance of cytopenia in chronic lymphocytic leukaemia/small lymphocytic lymphoma. Br J Haematol 2008; 141:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/19\">",
"      Moreno C, Hodgson K, Ferrer G, et al. Autoimmune cytopenia in chronic lymphocytic leukemia: prevalence, clinical associations, and prognostic significance. Blood 2010; 116:4771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/20\">",
"      Shanafelt TD, Geyer SM, Kay NE. Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL. Blood 2004; 103:1202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/21\">",
"      Shanafelt TD, Byrd JC, Call TG, et al. Narrative review: initial management of newly diagnosed, early-stage chronic lymphocytic leukemia. Ann Intern Med 2006; 145:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/22\">",
"      Giles FJ, O'Brien SM, Keating MJ. Chronic lymphocytic leukemia in (Richter's) transformation. Semin Oncol 1998; 25:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/23\">",
"      Kjeldsberg CR, Marty J. Prolymphocytic transformation of chronic lymphocytic leukemia. Cancer 1981; 48:2447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/24\">",
"      Melo JV, Catovsky D, Galton DA. The relationship between chronic lymphocytic leukaemia and prolymphocytic leukaemia. II. Patterns of evolution of 'prolymphocytoid' transformation. Br J Haematol 1986; 64:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/25\">",
"      Ohno T, Smir BN, Weisenburger DD, et al. Origin of the Hodgkin/Reed-Sternberg cells in chronic lymphocytic leukemia with \"Hodgkin's transformation\". Blood 1998; 91:1757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/26\">",
"      Fong D, Kaiser A, Spizzo G, et al. Hodgkin's disease variant of Richter's syndrome in chronic lymphocytic leukaemia patients previously treated with fludarabine. Br J Haematol 2005; 129:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/27\">",
"      Kanzler H, K&uuml;ppers R, Helmes S, et al. Hodgkin and Reed-Sternberg-like cells in B-cell chronic lymphocytic leukemia represent the outgrowth of single germinal-center B-cell-derived clones: potential precursors of Hodgkin and Reed-Sternberg cells in Hodgkin's disease. Blood 2000; 95:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/28\">",
"      Tsimberidou AM, O'Brien S, Kantarjian HM, et al. Hodgkin transformation of chronic lymphocytic leukemia: the M. D. Anderson Cancer Center experience. Cancer 2006; 107:1294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/29\">",
"      Molica S, Alberti A. Prognostic value of the lymphocyte doubling time in chronic lymphocytic leukemia. Cancer 1987; 60:2712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/30\">",
"      Montserrat E, Sanchez-Bisono J, Vi&ntilde;olas N, Rozman C. Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance. Br J Haematol 1986; 62:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/31\">",
"      Rossi D, Rasi S, Spina V, et al. Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood 2013; 121:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/32\">",
"      Lipshutz MD, Mir R, Rai KR, Sawitsky A. Bone marrow biopsy and clinical staging in chronic lymphocytic leukemia. Cancer 1980; 46:1422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/33\">",
"      Pangalis GA, Boussiotis VA, Kittas C. B-chronic lymphocytic leukemia. Disease progression in 150 untreated stage A and B patients as predicted by bone marrow pattern. Nouv Rev Fr Hematol 1988; 30:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/34\">",
"      Rozman C, Montserrat E, Rodr&iacute;guez-Fern&aacute;ndez JM, et al. Bone marrow histologic pattern--the best single prognostic parameter in chronic lymphocytic leukemia: a multivariate survival analysis of 329 cases. Blood 1984; 64:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/35\">",
"      Rozman C, Hernandez-Nieto L, Montserrat E, Brugues R. Prognostic significance of bone-marrow patterns in chronic lymphocytic leukaemia. Br J Haematol 1981; 47:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/36\">",
"      Wierda WG, O'Brien S, Wang X, et al. Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment. J Clin Oncol 2009; 27:1637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/37\">",
"      Fayad L, Keating MJ, Reuben JM, et al. Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood 2001; 97:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/38\">",
"      Moreno A, Villar ML, C&aacute;mara C, et al. Interleukin-6 dimers produced by endothelial cells inhibit apoptosis of B-chronic lymphocytic leukemia cells. Blood 2001; 97:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/39\">",
"      Delgado J, Pratt G, Phillips N, et al. Beta2-microglobulin is a better predictor of treatment-free survival in patients with chronic lymphocytic leukaemia if adjusted according to glomerular filtration rate. Br J Haematol 2009; 145:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/40\">",
"      Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94:1840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/41\">",
"      Hamblin TJ, Davis Z, Gardiner A, et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94:1848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/42\">",
"      Fais F, Ghiotto F, Hashimoto S, et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest 1998; 102:1515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/43\">",
"      Ritgen M, Lange A, Stilgenbauer S, et al. Unmutated immunoglobulin variable heavy-chain gene status remains an adverse prognostic factor after autologous stem cell transplantation for chronic lymphocytic leukemia. Blood 2003; 101:2049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/44\">",
"      Kr&ouml;ber A, Seiler T, Benner A, et al. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 2002; 100:1410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/45\">",
"      Tobin G, Thunberg U, Johnson A, et al. Somatically mutated Ig V(H)3-21 genes characterize a new subset of chronic lymphocytic leukemia. Blood 2002; 99:2262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/46\">",
"      Hamblin TJ, Davis ZA, Oscier DG. Determination of how many immunoglobulin variable region heavy chain mutations are allowable in unmutated chronic lymphocytic leukaemia - long-term follow up of patients with different percentages of mutations. Br J Haematol 2008; 140:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/47\">",
"      Lin KI, Tam CS, Keating MJ, et al. Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens. Blood 2009; 113:3168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/48\">",
"      Chevallier P, Penther D, Avet-Loiseau H, et al. CD38 expression and secondary 17p deletion are important prognostic factors in chronic lymphocytic leukaemia. Br J Haematol 2002; 116:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/49\">",
"      Ibrahim S, Keating M, Do KA, et al. CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood 2001; 98:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/50\">",
"      Ghia P, Guida G, Stella S, et al. The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression. Blood 2003; 101:1262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/51\">",
"      Mainou-Fowler T, Dignum H, Taylor PR, et al. Quantification improves the prognostic value of CD38 expression in B-cell chronic lymphocytic leukaemia. Br J Haematol 2002; 118:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/52\">",
"      D&uuml;rig J, Naschar M, Schm&uuml;cker U, et al. CD38 expression is an important prognostic marker in chronic lymphocytic leukaemia. Leukemia 2002; 16:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/53\">",
"      D'Arena G, Musto P, Cascavilla N, et al. CD38 expression correlates with adverse biological features and predicts poor clinical outcome in B-cell chronic lymphocytic leukemia. Leuk Lymphoma 2001; 42:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/54\">",
"      Joshi AD, Hegde GV, Dickinson JD, et al. ATM, CTLA4, MNDA, and HEM1 in high versus low CD38 expressing B-cell chronic lymphocytic leukemia. Clin Cancer Res 2007; 13:5295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/55\">",
"      D&uuml;rig J, N&uuml;ckel H, Cremer M, et al. ZAP-70 expression is a prognostic factor in chronic lymphocytic leukemia. Leukemia 2003; 17:2426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/56\">",
"      Rassenti LZ, Jain S, Keating MJ, et al. Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood 2008; 112:1923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/57\">",
"      Chen L, Widhopf G, Huynh L, et al. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood 2002; 100:4609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/58\">",
"      Shanafelt TD, Drake MT, Maurer MJ, et al. Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia. Blood 2011; 117:1492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/59\">",
"      Wierda WG, Johnson MM, Do KA, et al. Plasma interleukin 8 level predicts for survival in chronic lymphocytic leukaemia. Br J Haematol 2003; 120:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/60\">",
"      Manshouri T, Do KA, Wang X, et al. Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood 2003; 101:2507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/61\">",
"      Maurer MJ, Cerhan JR, Katzmann JA, et al. Monoclonal and polyclonal serum free light chains and clinical outcome in chronic lymphocytic leukemia. Blood 2011; 118:2821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/62\">",
"      Morabito F, De Filippi R, Laurenti L, et al. The cumulative amount of serum-free light chain is a strong prognosticator in chronic lymphocytic leukemia. Blood 2011; 118:6353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/63\">",
"      Koller C, Bekele BN, Zhou X, et al. Plasma thrombopoietin compared with immunoglobulin heavy-chain mutation status as a predictor of survival in chronic lymphocytic leukemia. Blood 2006; 108:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/64\">",
"      Stamatopoulos B, Meuleman N, Haibe-Kains B, et al. microRNA-29c and microRNA-223 down-regulation has in vivo significance in chronic lymphocytic leukemia and improves disease risk stratification. Blood 2009; 113:5237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/65\">",
"      Visone R, Rassenti LZ, Veronese A, et al. Karyotype-specific microRNA signature in chronic lymphocytic leukemia. Blood 2009; 114:3872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/66\">",
"      Vasconcelos Y, Davi F, Levy V, et al. Binet's staging system and VH genes are independent but complementary prognostic indicators in chronic lymphocytic leukemia. J Clin Oncol 2003; 21:3928.",
"     </a>",
"    </li>",
"    <li>",
"     Montserrat E, Vinolas N, Reverter JC, et al. Chronic lymphocytic leukemia in early stage \"smoldering\" and \"active\" forms in chronic lymphocytic leukemia: Scientifc advances and clinical developments. Cheston BD (Ed). Marcel Dekker, New York 1993. p.281.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/68\">",
"      Matutes E, Owusu-Ankomah K, Morilla R, et al. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia 1994; 8:1640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/69\">",
"      Effects of chlorambucil and therapeutic decision in initial forms of chronic lymphocytic leukemia (stage A): results of a randomized clinical trial on 612 patients. The French Cooperative Group on Chronic Lymphocytic Leukemia. Blood 1990; 75:1414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/70\">",
"      Montserrat E, Rozman C. Chronic lymphocytic leukaemia: prognostic factors and natural history. Baillieres Clin Haematol 1993; 6:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/71\">",
"      Munta&ntilde;ola A, Bosch F, Arguis P, et al. Abdominal computed tomography predicts progression in patients with Rai stage 0 chronic lymphocytic leukemia. J Clin Oncol 2007; 25:1576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/72\">",
"      French Cooperative Group on Chronic Lymphocytic Leukaemia. Natural history of stage A chronic lymphocytic leukaemia untreated patients. Br J Haematol 1990; 76:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/73\">",
"      Molica S, Vitelli G, Levato D, et al. Increased serum levels of vascular endothelial growth factor predict risk of progression in early B-cell chronic lymphocytic leukaemia. Br J Haematol 1999; 107:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/74\">",
"      Chen H, Treweeke AT, West DC, et al. In vitro and in vivo production of vascular endothelial growth factor by chronic lymphocytic leukemia cells. Blood 2000; 96:3181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/75\">",
"      Michallet M, Archimbaud E, Bandini G, et al. HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia. European Group for Blood and Marrow Transplantation and the International Bone Marrow Transplant Registry. Ann Intern Med 1996; 124:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/76\">",
"      Thornton PD, Fernandez C, Giustolisi GM, et al. CD38 expression as a prognostic indicator in chronic lymphocytic leukaemia. Hematol J 2004; 5:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/77\">",
"      Gentile M, Mauro FR, Calabrese E, et al. The prognostic value of CD38 expression in chronic lymphocytic leukaemia patients studied prospectively at diagnosis: a single institute experience. Br J Haematol 2005; 130:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/78\">",
"      Rosenwald A, Alizadeh AA, Widhopf G, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 2001; 194:1639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/79\">",
"      Klein U, Tu Y, Stolovitzky GA, et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med 2001; 194:1625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/80\">",
"      Damle RN, Ghiotto F, Valetto A, et al. B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes. Blood 2002; 99:4087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/81\">",
"      D&uuml;rig J, N&uuml;ckel H, H&uuml;ttmann A, et al. Expression of ribosomal and translation-associated genes is correlated with a favorable clinical course in chronic lymphocytic leukemia. Blood 2003; 101:2748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/82\">",
"      Rai KR, Chiorazzi N. Determining the clinical course and outcome in chronic lymphocytic leukemia. N Engl J Med 2003; 348:1797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/83\">",
"      Guarini A, Gaidano G, Mauro FR, et al. Chronic lymphocytic leukemia patients with highly stable and indolent disease show distinctive phenotypic and genotypic features. Blood 2003; 102:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/84\">",
"      Wierda WG, O'Brien S, Wang X, et al. Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia. J Clin Oncol 2011; 29:4088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/85\">",
"      Degan M, Bomben R, Bo MD, et al. Analysis of IgV gene mutations in B cell chronic lymphocytic leukaemia according to antigen-driven selection identifies subgroups with different prognosis and usage of the canonical somatic hypermutation machinery. Br J Haematol 2004; 126:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/86\">",
"      Haslinger C, Schweifer N, Stilgenbauer S, et al. Microarray gene expression profiling of B-cell chronic lymphocytic leukemia subgroups defined by genomic aberrations and VH mutation status. J Clin Oncol 2004; 22:3937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/87\">",
"      Dickinson JD, Smith LM, Sanger WG, et al. Unique gene expression and clinical characteristics are associated with the 11q23 deletion in chronic lymphocytic leukaemia. Br J Haematol 2005; 128:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/88\">",
"      Kienle DL, Korz C, Hosch B, et al. Evidence for distinct pathomechanisms in genetic subgroups of chronic lymphocytic leukemia revealed by quantitative expression analysis of cell cycle, activation, and apoptosis-associated genes. J Clin Oncol 2005; 23:3780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/89\">",
"      Grabowski P, Hultdin M, Karlsson K, et al. Telomere length as a prognostic parameter in chronic lymphocytic leukemia with special reference to VH gene mutation status. Blood 2005; 105:4807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/90\">",
"      Oppezzo P, Vasconcelos Y, Settegrana C, et al. The LPL/ADAM29 expression ratio is a novel prognosis indicator in chronic lymphocytic leukemia. Blood 2005; 106:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/91\">",
"      Calin GA, Ferracin M, Cimmino A, et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005; 353:1793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/92\">",
"      Byrd JC, Gribben JG, Peterson BL, et al. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. J Clin Oncol 2006; 24:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/93\">",
"      Kr&ouml;ber A, Bloehdorn J, Hafner S, et al. Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia. J Clin Oncol 2006; 24:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/94\">",
"      Deaglio S, Vaisitti T, Aydin S, et al. In-tandem insight from basic science combined with clinical research: CD38 as both marker and key component of the pathogenetic network underlying chronic lymphocytic leukemia. Blood 2006; 108:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/95\">",
"      Dicker F, Schnittger S, Haferlach T, et al. Immunostimulatory oligonucleotide-induced metaphase cytogenetics detect chromosomal aberrations in 80% of CLL patients: A study of 132 CLL cases with correlation to FISH, IgVH status, and CD38 expression. Blood 2006; 108:3152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/96\">",
"      Tinhofer I, Rubenzer G, Holler C, et al. Expression levels of CD38 in T cells predict course of disease in male patients with B-chronic lymphocytic leukemia. Blood 2006; 108:2950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/97\">",
"      Del Poeta G, Maurillo L, Venditti A, et al. Clinical significance of CD38 expression in chronic lymphocytic leukemia. Blood 2001; 98:2633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/98\">",
"      Friedman DR, Weinberg JB, Barry WT, et al. A genomic approach to improve prognosis and predict therapeutic response in chronic lymphocytic leukemia. Clin Cancer Res 2009; 15:6947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/99\">",
"      Oscier DG, Gardiner AC, Mould SJ, et al. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood 2002; 100:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/100\">",
"      Dreger P, Stilgenbauer S, Benner A, et al. The prognostic impact of autologous stem cell transplantation in patients with chronic lymphocytic leukemia: a risk-matched analysis based on the VH gene mutational status. Blood 2004; 103:2850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/101\">",
"      Ritgen M, Stilgenbauer S, von Neuhoff N, et al. Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCR. Blood 2004; 104:2600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/102\">",
"      Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003; 348:1764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/103\">",
"      Wiestner A, Rosenwald A, Barry TS, et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 2003; 101:4944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/104\">",
"      Orchard JA, Ibbotson RE, Davis Z, et al. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet 2004; 363:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/105\">",
"      Schwaenen C, Nessling M, Wessendorf S, et al. Automated array-based genomic profiling in chronic lymphocytic leukemia: development of a clinical tool and discovery of recurrent genomic alterations. Proc Natl Acad Sci U S A 2004; 101:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/106\">",
"      Del Principe MI, Del Poeta G, Buccisano F, et al. Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia. Blood 2006; 108:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/107\">",
"      Rassenti LZ, Huynh L, Toy TL, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 2004; 351:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/108\">",
"      Khouri IF, Saliba RM, Admirand J, et al. Graft-versus-leukaemia effect after non-myeloablative haematopoietic transplantation can overcome the unfavourable expression of ZAP-70 in refractory chronic lymphocytic leukaemia. Br J Haematol 2007; 137:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/109\">",
"      Grever MR, Lucas DM, Dewald GW, et al. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. J Clin Oncol 2007; 25:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/110\">",
"      Byrd JC, Lin TS, Dalton JT, et al. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 2007; 109:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/111\">",
"      Lin TS, Fischer B, Moran ME, et al. Flavopiridol, fludarabine and rituximab (FFR) is an active regimen in indolent B-cell lymphoproliferative disorders and mantle cell lymphoma (MCL) (abstract). J Clin Oncol 2006; 24:446s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/112\">",
"      Wierda WG. Current and investigational therapies for patients with CLL. Hematology Am Soc Hematol Educ Program 2006; :285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/113\">",
"      Gribben JG. How I treat CLL up front. Blood 2010; 115:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/114\">",
"      Sch&ouml;llkopf C, Rosendahl D, Rostgaard K, et al. Risk of second cancer after chronic lymphocytic leukemia. Int J Cancer 2007; 121:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/115\">",
"      Maddocks-Christianson K, Slager SL, Zent CS, et al. Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemia. Br J Haematol 2007; 139:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/6/15466/abstract/116\">",
"      Solh M, Rai KR, Peterson BL, et al. The impact of initial fludarabine therapy on transformation to Richter syndrome or prolymphocytic leukemia in patients with chronic lymphocytic leukemia: analysis of an intergroup trial (CALGB 9011). Leuk Lymphoma 2013; 54:252.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4489 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-41.78.124.10-00EF7A87C0-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_6_15466=[""].join("\n");
var outline_f15_6_15466=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL STAGING AND PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Rai staging system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Binet staging system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      OTHER PROGNOSTIC FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Lymphocyte doubling time",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Genetic abnormalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Bone marrow histologic pattern",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Beta-2 microglobulin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - IgVH mutation status",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - CD38",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - ZAP 70",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Other markers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Low and intermediate risk groups",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Indolent or smoldering disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Other predictors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Defining good and poor prognostic groups",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Role of CD38, ZAP-70, and VH gene mutation status",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      HISTOLOGIC TRANSFORMATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Prolymphocytoid transformation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Richter's transformation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Acute leukemic transformation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4489\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4489|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/9/156\" title=\"figure 1\">",
"      CLL survival beta 2 microglob",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/13/10463\" title=\"figure 2\">",
"      ZAP-70 and Vh genes in CLL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/61/30686\" title=\"figure 3\">",
"      CLL nomogram for time to first treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4489|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/54/12135\" title=\"picture 1\">",
"      Richters transformation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4489|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/23/10619\" title=\"table 1\">",
"      Rai staging system CLL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/50/811\" title=\"table 2\">",
"      Binet staging system CLL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/18/29995\" title=\"table 3\">",
"      Prognostic features CLL",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/28/18887?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of small lymphocytic lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35017?source=related_link\">",
"      Overview of the complications of chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/42/29352?source=related_link\">",
"      Overview of the treatment of chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3609?source=related_link\">",
"      Pathobiology and treatment of Richter's transformation in chronic lymphocytic leukemia/small lymphocytic lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/38/35431?source=related_link\">",
"      Pathologic features, diagnosis, and differential diagnosis of chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/23/42361?source=related_link\">",
"      Pathophysiology and genetic features of chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34886?source=related_link\">",
"      Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?6/10/6309?source=related_link\">",
"      Patient information: Chronic lymphocytic leukemia (CLL) in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/55/36730?source=related_link\">",
"      Prognosis of acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/46/30442?source=related_link\">",
"      Treatment of relapsed or refractory chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/21/3417?source=related_link\">",
"      Treatment of vitamin D deficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/2/42022?source=related_link\">",
"      ZAP-70 deficiency",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_6_15467="Urodynamic testing";
var content_f15_6_15467=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F75195&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F75195&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Types of urodynamic studies and measurements",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Documentation of objective evidence of incontinence upon provocation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Volume at first desire to void",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intravesical, urethral, abdominal pressures during bladder filling and voiding",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Calculation of detrusor pressure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Urine flow rate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Residual bladder volume",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Leak point pressure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pressure flow studies relating flow rates to changes in pressure during bladder emptying",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Surface electromyography to indirectly measure pelvic floor and sphincter muscle contractility",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Videourodynamics to combine routine urodynamic studies with X-ray or ultrasound imaging",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ambulatory urodynamics to evaluate patients while they perform their usual activities",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_6_15467=[""].join("\n");
var outline_f15_6_15467=null;
var title_f15_6_15468="Causes DIC children";
var content_f15_6_15468=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F59455&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F59455&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of disseminated intravascular coagulation in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bacteria - Meningococcus, Gram positive and negative bacterial sepsis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Virus - Human immunodeficiency virus, Varicella-zoster, cytomegalovirus (CMV), Dengue fever, Ebola virus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fungal - Candida, Aspergillus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rickettsia - Rocky Mountain Spotted fever",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Malaria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Injury",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Brain injury",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Crush injury",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Massive burns",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Extensive surgery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Malignancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute promyelocytic leukemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute lymphoblastic leukemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Microangiopathic disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Giant hemangioma - Kasabach-Merritt syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Gastrointestinal disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute and chronic liver disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reye's syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Neonatal causes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Birth asphyxia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Respiratory distress syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Meconium aspiration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amniotic fluid aspiration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Necrotizing enterocolitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Congenital infections - Neonatal CMV, Herpes simplex virus, bacterial or fungal infections",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Congenital thrombotic disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Homozygous deficiencies of proteins C and S",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antithrombin III deficiency",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Wendy Wong, MD and Bertil Glader MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_6_15468=[""].join("\n");
var outline_f15_6_15468=null;
var title_f15_6_15469="Causes viral CNS infection";
var content_f15_6_15469=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F53862&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F53862&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Viral infections of the central nervous system",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Meningitis",
"       </td>",
"       <td class=\"subtitle1\">",
"        Encephalitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">",
"        Enteroviruses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Coxsackie A and B viruses",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Echoviruses",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Polioviruses",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">",
"        Arthropod-borne viruses (arboviruses)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        West Nile virus",
"       </td>",
"       <td>",
"        Infrequent",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        St. Louis encephalitis virus",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        California encephalitis virus",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Eastern encephalitis virus",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Western encephalitis virus",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Venezuelan equine encephalitis virus",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        Infrequent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Colorado tick fever",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        Infrequent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Powassan encephalitis",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">",
"        Herpesviruses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Herpes simplex type I",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Herpes simplex type 2",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cytomegalovirus",
"       </td>",
"       <td>",
"        Infrequent",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Varicella zoster virus",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"       <td>",
"        Infrequent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Epstein Barr virus",
"       </td>",
"       <td>",
"        Infrequent",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Simian herpes B virus",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">",
"        Other viruses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Human immunodeficiency virus",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rabies virus",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lymphocytic choriomeningitis virus",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"       <td>",
"        Infrequent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Influenza virus",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mumps virus",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"       <td>",
"        Infrequent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Measles",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * The terms common, infrequent, and rare refer to the propensity of a viral CNS infection to result in either meningitis or encephalitis and not to how commonly a specific virus causes CNS infection.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_6_15469=[""].join("\n");
var outline_f15_6_15469=null;
var title_f15_6_15470="Outcome repeat valvuloplasty";
var content_f15_6_15470=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F65758&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F65758&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Outcome after repeat PMBV is related to comorbid diseases",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 377px; height: 439px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In a group of 36 patients who underwent repeat percutaneous mitral balloon valvulotomy for mitral valve restenosis developing 37 months after the first procedure, the presence of a comorbid disease significantly reduced overall survival (panel A) and event-free survival (panel B).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Pathan AZ, Mahdi NA, Leon MN, et al. J Am Coll Cardiol 1999; 34:49.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_6_15470=[""].join("\n");
var outline_f15_6_15470=null;
var title_f15_6_15471="1st mcp sesamoids";
var content_f15_6_15471=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F80813&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F80813&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    First metacarpal phalangeal joint sesamoids (white arrows)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 405px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This oblique view shows the two most common foot sesamoids: medial (ie, tibial) and lateral (ie, fibular) sesamoids below the metatarsophalangeal joint of the great toe. A nondisplaced, transverse fracture of the proximal phalanx of the little toe (black arrow) can also be seen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert L Hatch, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_6_15471=[""].join("\n");
var outline_f15_6_15471=null;
